Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

S K Sarin, M Kumar, G K Lau, Z Abbas, H L Y Chan, C J Chen, D S Chen, H L Chen, P J Chen, R N Chien, A K Dokmeci, Ed Gane, J L Hou, W Jafri, J Jia, J H Kim, C L Lai, H C Lee, S G Lim, C J Liu, S Locarnini, M Al Mahtab, R Mohamed, M Omata, J Park, T Piratvisuth, B C Sharma, J Sollano, F S Wang, L Wei, M F Yuen, S S Zheng, J H Kao, S K Sarin, M Kumar, G K Lau, Z Abbas, H L Y Chan, C J Chen, D S Chen, H L Chen, P J Chen, R N Chien, A K Dokmeci, Ed Gane, J L Hou, W Jafri, J Jia, J H Kim, C L Lai, H C Lee, S G Lim, C J Liu, S Locarnini, M Al Mahtab, R Mohamed, M Omata, J Park, T Piratvisuth, B C Sharma, J Sollano, F S Wang, L Wei, M F Yuen, S S Zheng, J H Kao

Abstract

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts' personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

Keywords: Acute hepatitis; Guidelines; HBV.

Figures

Fig. 1
Fig. 1
Treatment indications for chronic HBV-infected patients with cirrhosis or reactivation of chronic HBV infection
Fig. 2
Fig. 2
Treatment indications for noncirrhotic HBeAg-positive chronic HBV-infected patients
Fig. 3
Fig. 3
Treatment indications for noncirrhotic HBeAg-negative chronic HBV-infected patients
Fig. 4
Fig. 4
Reverse transcriptase mutations associated with drug resistance
Fig. 5
Fig. 5
Cumulative incidence of antiviral resistance in long-term studies of NA therapy
Fig. 6
Fig. 6
Prophylaxis for prevention of HBV graft recurrence following LT
Fig. 7
Fig. 7
Treatment of CHB infection in HIV infected individuals
Fig. 8
Fig. 8
Treatment of HBV–HCV coinfected patients

References

    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–926. doi: 10.1136/.
    1. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106–1110. doi: 10.1136/.
    1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219. doi: 10.1016/j.vaccine.2011.12.116.
    1. Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403–410. doi: 10.1016/j.jhep.2009.04.003.
    1. Clements CJ, Baoping Y, Crouch A, et al. Progress in the control of hepatitis B infection in the western Pacific region. Vaccine. 2006;24:1975–1982. doi: 10.1016/j.vaccine.2005.11.035.
    1. Chan HL, Jia J. Chronic hepatitis B in Asia-new insights from the past decade. J Gastroenterol Hepatol. 2011;26(Suppl. 1):131–137. doi: 10.1111/j.1440-1746.2010.06544.x.
    1. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1–20.
    1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107. doi: 10.1046/j.1365-2893.2003.00487.x.
    1. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B Vaccination IN Taiwan: impact and Implication for future strategies. Gastroenterology. 2007;132:1287–1293. doi: 10.1053/j.gastro.2007.02.055.
    1. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA. 2013;310:974–976. doi: 10.1001/jama.2013.276701.
    1. Liang X, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009;27:6550–6557. doi: 10.1016/j.vaccine.2009.08.048.
    1. Kim H, Shin AR, Chung HH, Kim MK, Lee JS, Shim JJ, Kim BH. Recent trends in hepatitis B virus infection in the general Korean population. Korean J Intern Med. 2013;28:413–419. doi: 10.3904/kjim.2013.28.4.413.
    1. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174. doi: 10.1056/NEJMoa013215.
    1. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Hepatology. 2006;45:529–538. doi: 10.1016/j.jhep.2006.05.013.
    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN2008. Int J Cancer. 2010;127:2893–2917. doi: 10.1002/ijc.25516.
    1. Hashem B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. doi: 10.1053/j.gastro.2011.12.061.
    1. Nayak NC, Panda SK, Zuckerman AJ, Bhan MK, Guha DK. Dynamics and impact of perinatal transmission of hepatitis B virus in North India. J Med Virol. 1987;21(2):137–145. doi: 10.1002/jmv.1890210205.
    1. Pande C, Sarin SK, Patra S, Bhutia K, Mishra SK, Pahuja S, et al. Prevalence, risk factors and virological profile of chronic hepatitis B virus infection in pregnant women in India. J Med Virol. 2011;83(6):962–967. doi: 10.1002/jmv.22017.
    1. Liaw YF, Kao JH, Piratwisuth T, Chan HLK, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–561. doi: 10.1007/s12072-012-9365-4.
    1. Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol. 2014;12:16–26. doi: 10.1016/j.cgh.2013.04.036.
    1. Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, Chauhan R, Bose S. Virological and histological features of chronic hepatitis b virus infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134(5):1376–1384. doi: 10.1053/j.gastro.2008.02.075.
    1. Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11(4):209–219. doi: 10.1038/nrgastro.2013.216.
    1. Kumar M, Jain S, Sharma BC, Sarin SK. Differentiating acute viral hepatitis B from the first episode of exacerbation of chronic hepatitis B. Dig Dis Sci. 2006;51(3):594–599. doi: 10.1007/s10620-006-3175-2.
    1. Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, et al. Higher efficacy of sequential therapy with Interferon alfa and lamivudine combination compared to Lamivudine monotherapy in HBeAg positive chronic hepatitis B patients: a controlled trial. Am J Gastroenterol. 2005;100(11):2463–2471. doi: 10.1111/j.1572-0241.2005.00247.x.
    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185. doi: 10.1016/j.jhep.2012.02.010.
    1. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829–834. doi: 10.1016/j.amjmed.2003.12.040.
    1. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005;54:1610–1614. doi: 10.1136/gut.2005.065136.
    1. Kim HC, Nam CM, Jee SH, et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328:980–983. doi: 10.1136/bmj.38050.593634.63.
    1. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10. doi: 10.7326/0003-4819-137-1-200207020-00006.
    1. Kao JH, Chen DS. Critical analysis of the immune tolerance phase of chronic HBV infection: natural history and diagnosis. Curr Hepat Rep. 2008;7:5–11. doi: 10.1007/s11901-008-0015-1.
    1. Tseng TC, Kao JH. Treating immune-tolerant hepatitis B. J Viral Hepat. 2015;22(2):77–84. doi: 10.1111/jvh.12370.
    1. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immunetolerant phase. Hepatology. 2007;46:395–401. doi: 10.1002/hep.21724.
    1. Andreani T, Serfaty L, Mohand D, et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histological findings and outcome. Clin Gastroenterol Hepatol. 2007;5:636–641. doi: 10.1016/j.cgh.2007.01.005.
    1. Park JY, Park YN, Kim DY, et al. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels. J Viral Hepat. 2008;15:615–621. doi: 10.1111/j.1365-2893.2008.00989.x.
    1. Kumar M, Sarin SK. Hepatitis B virus immuno tolerant patients: need to differentiate patients with or without liver disease. Gastroenterology. 2009;137(2):742–743. doi: 10.1053/j.gastro.2009.05.058.
    1. Chen JD, Yang HI, Iloeje UH, Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology. 2010;138(5):1747–1754. doi: 10.1053/j.gastro.2010.01.042.
    1. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14:147–152. doi: 10.1111/j.1365-2893.2006.00810.x.
    1. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology. 1983;84:216–219.
    1. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol. 2004;72:363–369. doi: 10.1002/jmv.10534.
    1. Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH, Negus SE, McMahon BJ. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology. 2007;133(5):1452–1457. doi: 10.1053/j.gastro.2007.08.010.
    1. Chu CM, Liaw YF. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B. J Hepatol. 2005;43:411–417. doi: 10.1016/j.jhep.2005.03.018.
    1. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493–496. doi: 10.1002/hep.1840080310.
    1. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52:514–522. doi: 10.1016/j.jhep.2010.01.014.
    1. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508–513. doi: 10.1016/j.jhep.2010.01.007.
    1. Lin CL, Liao LY, Liu CJ, Yu MW, Chen PJ, Lai MY, et al. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels. Hepatology. 2007;45(5):1193–1198. doi: 10.1002/hep.21585.
    1. Tapp E, Jones DM, Hollanders D, Dymock IW. Serial liver biopsies in blood donors with persistent HBs antigenaemia. J Clin Pathol. 1976;29:884–886. doi: 10.1136/jcp.29.10.884.
    1. Dragosics B, Ferenci P, Hitchman E, Denk H. Long-term followup study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histological evaluation of 242 cases. Hepatology. 1987;7:302–306. doi: 10.1002/hep.1840070215.
    1. de Franchis R, D’Arminio A, Vecchi M, Ronchi G, Del Ninno E, Parravicini A, et al. Chronic asymptomatic HBsAgs: histological abnormalities and diagnostic and prognostic value of serological markers of the HBV. Gastroenterology. 1980;79:521–527.
    1. Kumar M, Sarin SK. Liver biopsy in Chronic hepatitis B virus infected patients with normal ALT. Reply. Gastroenterology. 2008;135(5):1802–1803. doi: 10.1053/j.gastro.2008.09.049.
    1. Kumar M, Chauhan R, Gupta N, Hissar SS, Sakhuja P, Sarin SK. Spontaneous increase in ALT levels in asymptomatic chronic hepatitis B Virus Infected Patients. Gastroenterology. 2009;136(4):1272–1280. doi: 10.1053/j.gastro.2009.01.011.
    1. Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760–767. doi: 10.1016/j.jhep.2007.07.022.
    1. Yang LM, Xu KC, Zhao YL, et al. Clinical significance of liver biopsy in chronic hepatitis B patients with persistently normal transaminase. Chin J Dig Dis. 2002;3:150–153. doi: 10.1046/j.1443-9573.2002.00093.x.
    1. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. doi: 10.1001/jama.295.1.65.
    1. Hadziyannis SJ. Natural history of chronic hepatitis B in Euro-Mediterranean and African countries. J Hepatol. 2011;55(1):183–191. doi: 10.1016/j.jhep.2010.12.030.
    1. Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–1527. doi: 10.1053/jhep.2002.33638.
    1. Lok A, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001;120:1828–1853. doi: 10.1053/gast.2001.24839.
    1. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012;50:42
    1. Martinot-Peignoux M, Lapalus M, Laouénan C, et al. Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA. J Clin Virol. 2013;58:401–407. doi: 10.1016/j.jcv.2013.08.010.
    1. Tseng TC, Liu CJ, Yang HC, et al. Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus load. Hepatology. 2013;57:441–450. doi: 10.1002/hep.26041.
    1. Yim HJ, Lok AS. Natural history of chronic hepatitis B infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43:S173–S181. doi: 10.1002/hep.20956.
    1. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36:263–270. doi: 10.1016/S0168-8278(01)00266-5.
    1. Chu CJ, Hussain M, Lok AS. Quantitative serum HBVDNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408–1415. doi: 10.1002/hep.1840360617.
    1. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology. 2007;133(5):1458–1465. doi: 10.1053/j.gastro.2007.08.039.
    1. Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756–763. doi: 10.1053/j.gastro.2004.06.021.
    1. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089. doi: 10.1053/gast.2002.36026.
    1. Chen YC, Jeng WJ, Chu CM, Liaw YF. Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol. 2012;10:297–302. doi: 10.1016/j.cgh.2011.08.029.
    1. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554–559. doi: 10.1016/S0016-5085(00)70261-7.
    1. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology. 2003;37:19–26. doi: 10.1053/jhep.2003.50036.
    1. Tseng TC, Liu CJ, Yang HC, Chen CL, Yang WT, Tsai CS, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64(2):292–302. doi: 10.1136/gutjnl-2014-306977.
    1. Iloeje UH, Yang HI, Su J, Jen CL, Kuo E, You SL, et al. Viral load not serum ALT is the primary predictor of progression to cirrhosis in persons chronically infected with HBV: results from a long-term prospective study. J Hepatol. 2005;42:S180.
    1. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000;92:1159–1164. doi: 10.1093/jnci/92.14.1159.
    1. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265–272. doi: 10.1093/jnci/dji043.
    1. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124:327–334. doi: 10.1053/gast.2003.50053.
    1. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the US. Cancer. 2004;101:1009–1017. doi: 10.1002/cncr.20427.
    1. Liu CJ, Kao JH. Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to. J Semin Liver Dis. 2013;33(2):97–102. doi: 10.1055/s-0033-1345716.
    1. Suzuki Y, KobayashiM I, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol. 2005;76(1):33–39. doi: 10.1002/jmv.20320.
    1. Kobayashi M, Suzuki F, Arase Y, et al. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976–2001. J Gastroenterol. 2004;39(9):844–850. doi: 10.1007/s00535-004-1400-3.
    1. Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology. 2004;127(6):1733–1738. doi: 10.1053/j.gastro.2004.09.048.
    1. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B isassociated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122(7):1756–1762. doi: 10.1053/gast.2002.33588.
    1. Watanabe K, Takahashi T, Takahashi S, Okoshi S, Ichida T, Aoyagi Y. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. J Gastroenterol Hepatol. 2005;20(3):441–449. doi: 10.1111/j.1440-1746.2004.03572.x.
    1. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology. 2002;123(6):1848–1856. doi: 10.1053/gast.2002.37041.
    1. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology. 2004;39(6):1694–1701. doi: 10.1002/hep.20240.
    1. Sharma S, Sharma B, Singla B, et al. Clinical significance of genotypes and precore/basal core promoter mutations in HBV related chronic liver disease patients in North India. Dig Dis Sci. 2010;55(3):794–802. doi: 10.1007/s10620-009-1083-y.
    1. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virusmutations and the risk of hepatocellular carcinoma: a metaanalysis. J Natl Cancer Inst. 2009;101(15):1066–1082. doi: 10.1093/jnci/djp180.
    1. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13:211–220.
    1. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531. doi: 10.1056/NEJMoa033364.
    1. Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, Kim HS, et al. Report from a viral hepatitis policy forum on implementing the WHO framework for global action on viral hepatitis in North Asia. J Hepatol. 2013;59:1073–1080. doi: 10.1016/j.jhep.2013.06.029.
    1. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46:1034–1040. doi: 10.1002/hep.21784.
    1. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, Nakasato C, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047–1055. doi: 10.1093/cid/cis616.
    1. Torre F, Basso M, Giannini EG, Feasi M, Boni S, Grasso A, De Leo P, et al. Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden. J Med Virol. 2009;81:1882–1886. doi: 10.1002/jmv.21523.
    1. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat. 2011;18(Suppl. 1):1–16. doi: 10.1111/j.1365-2893.2011.01499.x.
    1. Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, Akita T, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54:185–195. doi: 10.1159/000324525.
    1. MacLachlan JH, Cowie BC. Liver cancer is the fastest increasing cause of cancer death in Australians. Med J Aust. 2012;197(9):492–493. doi: 10.5694/mja12.11481.
    1. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organisation; 1968.
    1. Mitchell AE, Colvin HM, Palmer Beasley R. Institute of medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010;51:729–733. doi: 10.1002/hep.23561.
    1. Perumalswami PV, Factor SH, Kapelusznik L, Friedman SL, Pan CQ, Chang C, Di Clemente F, et al. Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities. J Hepatol. 2013;58:890–897. doi: 10.1016/j.jhep.2013.01.004.
    1. Vedio AB, Ellam H, Rayner F, Stone B, Kudesia G, McKendrick MW, Green ST. Hepatitis B: report of prevalence and access to healthcare among Chinese residents in Sheffield UK. J Infect Public Health. 2013;6:448–455. doi: 10.1016/j.jiph.2013.05.004.
    1. Barratt A, Irwig L, Glasziou P, Cumming RG, Raffle A, Hicks N, et al. Users’ guides to the medical literature: XVII. How to use guidelines and recommendations about screening. Evidence-Based Medicine Working Group. JAMA 1999;281:2029–2034 (ref 112)
    1. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686. doi: 10.1053/j.gastro.2005.11.016.
    1. Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, Chen CJ. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5:921–931. doi: 10.1016/j.cgh.2007.06.015.
    1. Pollack H, Wang S, Wyatt L, Peng CH, Wan K, Trinh-Shevrin C, et al. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff. 2011;30:1974–1983. doi: 10.1377/hlthaff.2011.0700.
    1. Wiens A, Lenzi L, Venson R, Correr CJ, Rotta I, Pedroso ML, et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2013;33:144–151. doi: 10.1002/phar.1188.
    1. Liu C, Chen T, Lin J, Chen H, Chen J, Lin S, et al. Evaluation of the performance of four methods for detection of hepatitis B surface antigen and their application for testing 116,455 specimens. J Virol Methods. 2014;196:174–178. doi: 10.1016/j.jviromet.2013.10.039.
    1. Robotin MC, George J. Community-based hepatitis B screening: what works? Hepatol Int. 2014;8:478–492. doi: 10.1007/s12072-014-9562-4.
    1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–662. doi: 10.1002/hep.23190.
    1. Hou J, Liu Z, Gu F. Epidemiology and prevention of hepatitis B virus infection. Int J Med Sci. 2005;2:50–57. doi: 10.7150/ijms.2.50.
    1. Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149:203–213. doi: 10.1093/oxfordjournals.aje.a009792.
    1. Khan AJ, Luby SP, Fikree F, Karim A, Obaid S, Dellawala S, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ. 2000;78:956–963.
    1. Wang C, Wang Y, Huang X, Li X, Zhang T, Song M, et al. Prevalence and factors associated with hepatitis B immunization and infection among men who have sex with men in Beijing, China. PLoS One. 2012;7:e48219. doi: 10.1371/journal.pone.0048219.
    1. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–520. doi: 10.1111/j.1440-1746.2008.05384.x.
    1. Lin K, Vickery J. Screening for hepatitis B virus infection in pregnant women: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2009;150:874–876. doi: 10.7326/0003-4819-150-12-200906160-00012.
    1. Lu YP, Liang XJ, Xiao XM, Huang SM, Liu ZW, Li J, Hocher B, et al. Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. Clin Lab. 2014;60:571–586.
    1. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol. 2011;17:4321–4333. doi: 10.3748/wjg.v17.i38.4321.
    1. Cui F, Luo H, Wang F, Zheng H, Gong X, Chen Y, Wu Z, et al. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine. 2013;31(Suppl. 9):J36–J42. doi: 10.1016/j.vaccine.2012.11.061.
    1. Apata IW, Averhoff F, Pitman J, Bjork A, Yu J, Amin NA, Dhingra N, et al. Progress toward prevention of transfusion-transmitted hepatitis B and hepatitis C infection—sub-Saharan Africa, 2000–2011. MMWR Morb Mortal Wkly Rep. 2014;63:613–619.
    1. Ifland L. Promoting national blood systems in developing countries. Curr Opin Hematol. 2014;21:497–502. doi: 10.1097/MOH.0000000000000078.
    1. Rossi C, Schwartzman K, Oxlade O, Klein MB, Greenaway C. Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One. 2013;8:e78548. doi: 10.1371/journal.pone.0078548.
    1. Kao JH. Diagnosis of hepatitis B virus infection through serological and virological markers. Expert Rev Gastroenterol Hepatol. 2008;2:553–562. doi: 10.1586/17474124.2.4.553.
    1. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, et al. Serological pattern “anti-HBc alone”: report on a workshop. J Med Virol. 2000;62:450–455. doi: 10.1002/1096-9071(200012)62:4<450::AID-JMV9>;2-Y.
    1. Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology. 1988;8:766–770. doi: 10.1002/hep.1840080411.
    1. Chevillotte G, Durbec JP, Gerolami A, Berthezene P, Bidart JM, Camatte R. Interaction between hepatitis B virus and alcohol consumption in liver cirrhosis: an epidemiological study. Gastroenterology. 1983;85:141–145.
    1. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission ofhepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation. 1995;59(2):230–234. doi: 10.1097/00007890-199501270-00014.
    1. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl. 2001;7(1):51–58. doi: 10.1053/jlts.2001.20786.
    1. Mutimer D. Review article: hepatitis B and liver transplantation. AlimentPharmacol Ther. 2006;23(8):1031–1041.
    1. Wong VC, Ip HM, Reesink HW, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–926. doi: 10.1016/S0140-6736(84)92388-2.
    1. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. MJA. 2009;190(9):489–492.
    1. Chen SC, Toy M, Yeh JM, Wang JD, Resch S. Cost-effectiveness of augmenting universal hepatitis B vaccination with immunoglobin treatment. Pediatrics. 2013;131(4):e1135–e1143. doi: 10.1542/peds.2012-1262.
    1. Pais R, Rusu E, Ratziu V. The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. Clin Liver Dis. 2014;18(1):165–178. doi: 10.1016/j.cld.2013.09.015.
    1. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361–1367.
    1. Pawlotsky JM, Dusheiko G, Hatzakis A, Lau D, Lau G, Liang TJ, et al. Virological monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology. 2008;134:405–415. doi: 10.1053/j.gastro.2007.11.036.
    1. Hochberger S, Althof D, deSchrott RG, et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the Cobas® AmpliPrep/Cobas® TaqMan® system. J Clin Virol. 2006;35:373–380. doi: 10.1016/j.jcv.2006.01.003.
    1. Laperche S, Thibault V, Bouchardeau F, et al. Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study. J Clin Microbiol. 2006;44:3600–3607. doi: 10.1128/JCM.00732-06.
    1. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol. 2009;50:36–41. doi: 10.1016/j.jhep.2008.07.039.
    1. Bedossa P, Carrat F. Liver biopsy: the best, not gold standard. J Hepatol. 2009;50:1–3. doi: 10.1016/j.jhep.2008.10.014.
    1. Kang W, Kim SU, Ahn SH. Non-invasive prediction of forthcoming cirrhosis-related complications. World J Gastroenterol. 2014;20:2613–2623. doi: 10.3748/wjg.v20.i10.2613.
    1. Lee S, Kim do Y. Non-invasive diagnosis of hepatitis B-virus related cirrhosis. World J Gastroenterol. 2014;20:445–459. doi: 10.3748/wjg.v20.i2.445.
    1. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrsis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292–302. doi: 10.1002/hep.27382.
    1. de Lédinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol. 2012;56:833–839. doi: 10.1016/j.jhep.2011.10.017.
    1. Chon YE, Choi EH, Song KJ, Park JY, Kin do Y, Han KH, et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7:e44930. doi: 10.1371/journal.pone.0044930.
    1. Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int. 2013;7:356–368. doi: 10.1007/s12072-013-9439-y.
    1. Kim BK, Kim HS, Yoo EJ, Oh EJ, Park JY, Kim do Y. Risk assessment of clinical outcomes in Asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology. 2014;60:1911–1919. doi: 10.1002/hep.27389.
    1. Wong GL, Wong VW, Choi PC, Chan AW, Chim AM, Yiu KK, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther. 2011;16:165–172. doi: 10.3851/IMP1726.
    1. Kumar M, Rastogi A, Behari C, Singh T, Gupta E, Sharma P, et al. Analysis of discordance between transient elastography and liver biopsy for assessing liver fibrosis in chronic hepatitis B virus infection. Hepatol Int. 2013;7(1):134–143. doi: 10.1007/s12072-012-9380-5.
    1. Wong GL, Chan HL, Choi PC, Chan AW, Yu Z, Lai JW, et al. Non-invasive algorithm of enhamced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2014;39:197–208. doi: 10.1111/apt.12559.
    1. Park MS, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. Prognostic value of the combined use of transient 3elastography and fibrotest in patients with chronic hepatitis B. Liver Int. 2015;35(2):455–462. doi: 10.1111/liv.12678.
    1. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008;28:1067–1077. doi: 10.1111/j.1365-2036.2008.03816.x.
    1. Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:1134–1143. doi: 10.1093/jnci/djn243.
    1. Yang HI, Lee MH, Liu J, Chen CJ. Risk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia. World J Gastroenterol. 2014;20(20):6244–6251. doi: 10.3748/wjg.v20.i20.6244.
    1. Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology. 2005;48:23–28. doi: 10.1159/000082091.
    1. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50:80–88. doi: 10.1016/j.jhep.2008.07.023.
    1. Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010;28:1660–1665. doi: 10.1200/JCO.2009.26.2675.
    1. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28:2437–2444. doi: 10.1200/JCO.2009.27.4456.
    1. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011;12:568–574. doi: 10.1016/S1470-2045(11)70077-8.
    1. Tseng TC, Liu CJ, Yang HC, Su TH, Wang CC, Chen CL, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology. 2012;142:1140–1149. doi: 10.1053/j.gastro.2012.02.007.
    1. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58:546–554. doi: 10.1002/hep.26385.
    1. Chen TM, Chang CC, Huang PT, Wen CF, Lin CC. Performance of risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B) score in classifying treatment eligibility under 2012 Asian Pacific Association for the Study of the Liver (APASL) guideline for chronic hepatitis B patients. Aliment Pharmacol Ther. 2013;37:243–251. doi: 10.1111/apt.12144.
    1. Sarin SK, Kumar M. Predictive scores for hepatocellular carcinoma development in chronic hepatitis B virus infection:“does one size fit all?”. Gastroenterology. 2012;142:1038–1040. doi: 10.1053/j.gastro.2012.02.024.
    1. Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol. 2015;62(2):363–370. doi: 10.1016/j.jhep.2014.08.045.
    1. Wong GL, Chan HL, Chan HY, Tse PC, Tse YK, Mak CW, et al. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology. 2013;144:933–944. doi: 10.1053/j.gastro.2013.02.002.
    1. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point ofview of the hepatitis B virus. Carcinogenesis. 2011;32:1122–1132. doi: 10.1093/carcin/bgr108.
    1. Modabbernia A, Ashrafi M, Malekzadeh R, Poustchi H. A review of psychosocial issues in patients with chronic hepatitis B. Arch Iran Med. 2013;16(2):114–122.
    1. Zhuang G, Zhang M, Liu Y, Guo Y, Wu Q, Zhou K, et al. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls. Health Qual Life Outcomes. 2014;12:101. doi: 10.1186/1477-7525-12-101.
    1. Chao J, Song L, Zhang H, Zhu L, Tian L, Jin H, et al. Effects of comprehensive intervention on health-related quality of life in patients with chronic hepatitis B in China. BMC Health Serv Res. 2013;13:386. doi: 10.1186/1472-6963-13-386.
    1. Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, et al. Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol. 2010;52:176–182. doi: 10.1016/j.jhep.2009.11.007.
    1. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing WF, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72. doi: 10.1002/hep.23952.
    1. Chan HLY, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146:1240–1248. doi: 10.1053/j.gastro.2014.01.044.
    1. Nguyen LH, Chao D, Lim JK, Ayoub W, Nguyen MH. Histological changes in liver tissue from patients with chronic hepatitis B and minimal increases in levels of alanine aminotransferase: a meta-analysis and systematic review. Clin Gastroenterol Hepatol. 2014;12(8):1262–1266. doi: 10.1016/j.cgh.2013.11.038.
    1. Du X, Wang J, Shao L, et al. Histological improvement of long-term antiviral therapy in chronic hepatitis B patients with persistently normal alanine aminotransferase levels. J Viral Hepat. 2013;20:328–335. doi: 10.1111/jvh.12034.
    1. Yao GB, Zhu M, Cui AY. A 7-year study of lamivudine therapy for chronic hepatitis B virus e antigen-positive chronic hepatitis B patients in China. J Dig Dis. 2009;10:131–137. doi: 10.1111/j.1751-2980.2009.00375.x.
    1. Seto WK, Wong DK, Fung J, et al. Reduction of hepatitis B surface B antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923–931. doi: 10.1002/hep.26376.
    1. Lee HW, Lee HJ, Hwang JS, et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virological response in HBeAg-positive chronic hepatitis B. Hepatology. 2010;51:415–421. doi: 10.1002/hep.23323.
    1. Dai CY, Tseng TC, Wong GL, et al. Consolidation therapy for HBeAg-positive Asian chronic hepatitis B patients receiving lamivudine treatment: a multicentre study. J Antimicrob Chemother. 2013;68:2332–2338.
    1. Chen CH, Lu SN, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014;61(3):515–522. doi: 10.1016/j.jhep.2014.04.029.
    1. Fung SK, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis e antigen-negative chronic hepatitis B. J Viral Hepat. 2004;11:432–438. doi: 10.1111/j.1365-2893.2004.00556.x.
    1. Liu F, Wang L, Li XY, et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol. 2011;26:456–460. doi: 10.1111/j.1440-1746.2010.06492.x.
    1. Chan HL, Wong GL, Chim AM, et al. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther. 2011;16:1249–1257. doi: 10.3851/IMP1921.
    1. Chen CH, Lu SN, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Heaptol 2014;61(3):515–522
    1. Chan HL, Chen YC, Gane EJ, et al. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat. 2012;19:732–743. doi: 10.1111/j.1365-2893.2012.01600.x.
    1. Zoulim F, Locarnini S. Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance. Liver Int. 2013;33(Suppl. 1):116–124. doi: 10.1111/liv.12069.
    1. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495. doi: 10.1053/j.gastro.2008.10.026.
    1. Lee HW, Kang W, Ahn SH, Lee HJ, Hwang JS, Sohn JH, et al. Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. J Gastroenterol Hepatol. 2014;29(5):1049–1055. doi: 10.1111/jgh.12522.
    1. Hou J, Yin YK, Xu D, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology. 2008;47:447–454. doi: 10.1002/hep.22075.
    1. Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis B with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007;147:745–754. doi: 10.7326/0003-4819-147-11-200712040-00183.
    1. Wang Y, Thongsawat S, Gane EJ, et al. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat. 2013;20:e37–e46. doi: 10.1111/jvh.12025.
    1. Sun J, Xie Q, Tan D, et al. The 1-4-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study. Hepatology. 2014;59:1283–1293. doi: 10.1002/hep.26885.
    1. Lo AO, Wong VW, Wong GL. Efficacy of entecavir switch therapy in chronic hepatitis B with incomplete virological response to telbivudine. Antivir Ther. 2013;18:671–679. doi: 10.3851/IMP2526.
    1. Gane EJ, Deray G, Liaw YF, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology. 2014;146:138–146. doi: 10.1053/j.gastro.2013.09.031.
    1. Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat. 2014;21(12):873–881. doi: 10.1111/jvh.12217.
    1. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750–758. doi: 10.1002/hep.22414.
    1. Zeng M, Mao Y, Yao GB, et al. Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B. Liver Int. 2012;32:137–146. doi: 10.1111/j.1478-3231.2011.02641.x.
    1. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751. doi: 10.1053/j.gastro.2006.09.020.
    1. Seto WK, Liu K, Fung J, et al. Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir. Antivir Ther. 2012;17:1255–1262. doi: 10.3851/IMP2335.
    1. Kim YJ, Paik SW, Sinn DH, et al. Viral response at 6 months is associated with treatment outcome of adefovir add-on therapy for lamivudine-resistance. J Gastroenterol Hepatol. 2011;27:1454–1460. doi: 10.1111/j.1440-1746.2011.07050.x.
    1. Ong A, Wong VW, Wong GL, et al. Management options for lamivudine-resistant chronic hepatitis B patients with suboptimal virological suppression by adefovir. Aliment Pharmacol Ther. 2011;34:972–981. doi: 10.1111/j.1365-2036.2011.04833.x.
    1. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumerate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475. doi: 10.1016/S0140-6736(12)61425-1.
    1. Gordon SC, Krastev Z, Horban A, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013;58:505–513. doi: 10.1002/hep.26277.
    1. Berg T, Zoulim F, Moeller B, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2014;60:715–722. doi: 10.1016/j.jhep.2013.11.024.
    1. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs. emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980–988. doi: 10.1053/j.gastro.2013.12.028.
    1. Gracey DM, Snelling P, McKenzie P, et al. Tenofovir-associated Fanconi syndrome in patients with hepatitis B monoinfection. Antivir Ther. 2013;18:945–948. doi: 10.3851/IMP2649.
    1. Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of tretment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457–1464. doi: 10.1007/s10620-014-3486-7.
    1. Liu Y, Miller MD, Kitrinos KM. HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D. Liver Int. 2014;34(7):1025–1032. doi: 10.1111/liv.12343.
    1. Svarovskaia ES, Curtis M, Zhu Y, et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. J Viral Hepat. 2013;20:131–140. doi: 10.1111/j.1365-2893.2012.01638.x.
    1. Petersen J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients. An international multicenter cohort study. J Hepatol. 2012;56:520–526. doi: 10.1016/j.jhep.2011.09.018.
    1. Wang CC, Tseng KC, Peng CY, et al. Viral load and alanine aminotransferase correlate with serological response in chronic hepatitis B patients treated with entecavir. J Gastroenterol Hepatol. 2013;28:46–50. doi: 10.1111/j.1440-1746.2012.07269.x.
    1. Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther. 2012;35:1326–1335. doi: 10.1111/j.1365-2036.2012.05098.x.
    1. Seto WK, Lam YF, Fung J, et al. Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. J Gastroenterol Hepatol. 2014;29:1028–1034. doi: 10.1111/jgh.12476.
    1. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143:619–628. doi: 10.1053/j.gastro.2012.05.037.
    1. Yang YJ, Shim JH, Kim KM, et al. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. Hepatology. 2014;59:1303–1310. doi: 10.1002/hep.26910.
    1. Bang SJ, Kim BG, Shin JW, et al. Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. Dig Liver Dis. 2013;45(7):600–605
    1. Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107. doi: 10.1002/hep.26180.
    1. Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B paients: a propensity score analysis. J Hepatol. 2013;58:427–433. doi: 10.1016/j.jhep.2012.10.025.
    1. Wong GL, Chan HL, Mak CW, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537–1547. doi: 10.1002/hep.26301.
    1. Zoutendijk R, Peijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011;54:443–451. doi: 10.1002/hep.24406.
    1. Yang SC, Lee CM, Hu TH, et al. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrobiol Chemother. 2013;68:2154–2163. doi: 10.1093/jac/dkt147.
    1. Pan CQ, Hu KQ, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepat. 2012;19:213–219. doi: 10.1111/j.1365-2893.2011.01533.x.
    1. Yip B, Chaung K, Wong CR, et al. Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders. Dig Dis Sci. 2012;57:3011–3016. doi: 10.1007/s10620-012-2402-2.
    1. Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology. 2013;58:1888–1896. doi: 10.1002/hep.26549.
    1. Seto WK, Hui AJ, Wong VW, et al. Treatment cessation of entecavir in hepatitis B e antigen-negative chronic hepatitis B Asian patients: a multicenter prospective study. Gut. 2015;64(4):667–672. doi: 10.1136/gutjnl-2014-307237.
    1. Jin JL, Hu P, Lu JH, et al. Lactic acidosis during telbivudine treatment for HBV: a case report and literature review. World J Gastroenterol. 2013;19:5575–5580. doi: 10.3748/wjg.v19.i33.5575.
    1. Cohen SM, Levy RM, Jovanovich JF, Ahn J. Fatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis B. J Clin Gastroenterol. 2009;43:1008–1010. doi: 10.1097/MCG.0b013e31819c3945.
    1. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50:2001–2006. doi: 10.1002/hep.23346.
    1. Marzano A, Marengo A, Marietti M, Rizzetto M. Lactic acidosis during entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis. 2011;43(12):1027–1028. doi: 10.1016/j.dld.2011.06.013.
    1. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology. 2011;141:1212–1219. doi: 10.1053/j.gastro.2011.06.083.
    1. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009;49:1503–1514. doi: 10.1002/hep.22841.
    1. Lim YS, Lee JY, Shin JH, et al. Randomized trial of virological response during up to two years of entecavir-adefovir combination therapy in multi-drug-refractory chronic hepatitis B virus patients. Antimicrobial Agents Chemother. 2013;57:3369–3374. doi: 10.1128/AAC.00587-13.
    1. Kim BK, Ko SY, Kwon SY, et al. Virological response and muscular adverse events during long-term clevudine therapy in chronic hepatitis B. Hepat Mon. 2013;13:e6056.
    1. Choung BS, Kim IH, Jeon BJ, et al. Long-term treatment efficacy and safety of clevudine therapy in naïve patients with chronic hepatitis B. Gut Liver. 2012;6:486–492. doi: 10.5009/gnl.2012.6.4.486.
    1. Lai CL, Ahn SH, Lee KS, et al. Phase IIb multcentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut. 2014;63:996–1004. doi: 10.1136/gutjnl-2013-305138.
    1. Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533–540. doi: 10.1016/j.jhep.2014.10.035.
    1. Lai CL, Leung N, Teo EK, Telbivudine Phase II Investigator Group et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129(2):528–536. doi: 10.1016/j.gastro.2005.05.053.
    1. Liu F, Wang X, Wei F, Hu H, Zhang D, Hu P, et al. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis. Virol J. 2014;11:59. doi: 10.1186/1743-422X-11-59.
    1. Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology. 2012;143(3):619.e1–628.e1. doi: 10.1053/j.gastro.2012.05.037.
    1. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254–265. doi: 10.1002/hep.21698.
    1. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785–791. doi: 10.1053/jhep.2001.27563.
    1. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11–20. doi: 10.1016/j.jhep.2008.12.019.
    1. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxilfumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143. doi: 10.1053/j.gastro.2010.10.011.
    1. Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235–1240. doi: 10.1016/j.jhep.2011.03.030.
    1. Flischer RD, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J Hepatol. 2009;51:787–791. doi: 10.1016/j.jhep.2009.06.011.
    1. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611–1620. doi: 10.1002/hep.23905.
    1. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim DY, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011;53:1486–1493. doi: 10.1002/hep.24221.
    1. Marcellin P, Heathcote EJ, Buti M, Krastev Z, Jacobson I, de Man RA, et al. HBsAg kinetics in patients with chronic hepatitis B infection treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol. 2011;54:S297. doi: 10.1016/S0168-8278(11)60742-3.
    1. Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, et al. Relapse rate and associated-factor of recurrence after stopping NAs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8(7):e68568. doi: 10.1371/journal.pone.0068568.
    1. Chi H, Hansen BE, Arends P, Abu-Amara M, Yim C, Feld JJ, et al. Long-term nucleos(t)ide analogue consolidation therapy reduces risk of relapse in chronic hepatitis B. Hepatology. 2014;60:1090A–1091A.
    1. Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther. 2011;34(3):344–352. doi: 10.1111/j.1365-2036.2011.04738.x.
    1. Chen C-H, Lee C-M, Hu T-H, Hung C-H, Wang J-H, Lu S-N. The role of hepatitis B surface antigen quantification predict HBV reactivation after discontinuation of nucleos(t)ide analogs treatment in chronic hepatitis B patients with cirrhosis. Hepatology. 2014;60:1103A.
    1. Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2015;42(3):243–257. doi: 10.1111/apt.13272.
    1. Piratvisuth T. Immunomodulator therapy of chronic hepatitis B. Hepatol Int. 2008;2:140–146. doi: 10.1007/s12072-008-9046-5.
    1. Cooksley WGF, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis Be antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298–305. doi: 10.1046/j.1365-2893.2003.00450.x.
    1. Zhao H, Kurbanov F, Wan MB. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007;44:541–548. doi: 10.1086/511042.
    1. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352:2682–2695. doi: 10.1056/NEJMoa043470.
    1. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123–129. doi: 10.1016/S0140-6736(05)17701-0.
    1. Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2008;2:102–110. doi: 10.1007/s12072-007-9022-5.
    1. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459–467. doi: 10.1053/j.gastro.2008.05.031.
    1. Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591–1599. doi: 10.1002/hep.24555.
    1. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004;351:1206–1217. doi: 10.1056/NEJMoa040431.
    1. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136:2169e1–2179e4. doi: 10.1053/j.gastro.2009.03.006.
    1. Lampertico P, Vigano M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013;62:290–298. doi: 10.1136/gutjnl-2011-301430.
    1. Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007;46:388–394. doi: 10.1002/hep.21723.
    1. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol. 2007;102:96–104. doi: 10.1111/j.1572-0241.2006.01006.x.
    1. Chan HL, Wong VW, Chim AM, et al. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther. 2007;12:815–823.
    1. Wang YD, Zhao CY, Wang W, et al. Improved efficacy by individualized combination therapy with Peg IFN-a 2a and ADV in HBeAg positive chronic hepatitis B patients. Hepatogastroenterology. 2012;59:680–686. doi: 10.5754/hge11259.
    1. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen negative chronic hepatitis B. Antivir Ther. 2009;14:1165–1174. doi: 10.3851/IMP1466.
    1. Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol. 2015;62(1):41–47. doi: 10.1016/j.jhep.2014.08.021.
    1. Piccolo P, Lenci I, di Paolo D, et al. A randomized controlled trial of sequential peginterferon-alpha and telbivudine or vice versa for 48 weeks in HBeAg-negative chronic hepatitis B. Antivir Ther. 2013;18(1):57–64. doi: 10.3851/IMP2281.
    1. Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial) J Hepatol. 2014;61(4):777–784. doi: 10.1016/j.jhep.2014.05.044.
    1. Brouwer WP, Xie Q, Sonneveld MJ, Zhang N, Zhang Q, Tabak F, et al. Adding peginterferon to entecavir for HBeAg-positive chronic hepatitis B: a multicentre randomized trial (ARES study) Hepatology. 2015;61(5):1512–1522. doi: 10.1002/hep.27586.
    1. Jindal A, Kumar M, Sarin SK. Sequential therapy with tenofovir and pegylated interferon-alpha 2B versus tenofovir monotherapy in HBeAg positive chronic hepatitis B (CHB): an interim analysis. J Hepatol. 2014;60:S361–S522
    1. Marcellin P, et al. HBsAg loss with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2a (PEG) in chronic hepatitis B (CHB): results of a global randomized controlled trial. American Association for the Study of Liver Diseases (AASLD) Liver Meeting, Boston, abstract 193, 2014
    1. Kittner JM, Sprinzl MF, Grambihler A, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversionin a subgroup of patients with chronic hepatitis B. J Clin Virol. 2012;54:93–95. doi: 10.1016/j.jcv.2012.01.024.
    1. Chi H, Xie Q, Zhang N-P, Qi X, Liang C, Guo S, Guo Q, et al. Addition of peginterferon alfa-2b during long-term nucleos(t)ide analogue therapy increases HBeAg seroconversion and HBsAg decline—week 48 results from a multicenter randomized controlled trial (PEGON Study). Hepatology. 2014;60(S1):1106A
    1. Bourlière M, Rabiega P, Ganne-Carrié N, Serfaty L, Marcellin P, Pouget N, et al. HBsAg clearance after addition of 48 weeks of PEGIFN in HBeAg-negative CHB patients on nucleos(t)ide therapy with undetectable HBV DNA for at least one year: a multicenter randomized controlled phase III trial ANRS-HB06 PEGAN study: preliminary findings. Hepatology. 2014;60(S1):1094A
    1. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002–2009. doi: 10.1053/j.gastro.2009.08.061.
    1. Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther. 2011;16:629–637. doi: 10.3851/IMP1841.
    1. Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated nterferon. Liver Int. 2014;34(Suppl. 1):112–119. doi: 10.1111/liv.12400.
    1. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008;47:428–434. doi: 10.1002/hep.22065.
    1. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J Clin Virol. 2009;46:117–123. doi: 10.1016/j.jcv.2009.07.005.
    1. Yang HC, Chen CL, Shen YC, et al. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced hepatitis B e antigen seroconversion. Hepatology. 2013;57:934–943. doi: 10.1002/hep.26121.
    1. Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2012;56:67–75. doi: 10.1002/hep.25636.
    1. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:1151–1157. doi: 10.1002/hep.22744.
    1. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010;52:1251–1257 (ref 524)
    1. Piratvisuth T, Marcellin P. Further analysis is required to identify an early stopping rule for peginterferon therapy that is valid for all hepatitis B e antigen-positive patients. Hepatology. 2011;53:1054–1055. doi: 10.1002/hep.24136.
    1. Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872–880. doi: 10.1002/hep.26436.
    1. Rijckborst V, Hansen BE, Ferenci P, et al. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006–1011. doi: 10.1016/j.jhep.2011.12.007.
    1. Marcellin P, Bonino F, Yurdaydin C, et al. Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int. 2013;7:88–97. doi: 10.1007/s12072-012-9343-x.
    1. Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, et al. Baseline quantitative hepatitis B core antibody titer alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or NAleos(t)ide analogues. Gut 2015. doi:10.1136/gutjnl-2014-308546
    1. Su TH, Liu CJ, Yang HC, et al. Clinical significance and evolution of hepatic HBsAg expression in HBeAg-positive patients receiving interferon therapy. J Gastroenterol. 2014;49:356–362. doi: 10.1007/s00535-013-0840-z.
    1. Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012;142:513–520. doi: 10.1053/j.gastro.2011.11.025.
    1. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut. 2012;61(Suppl. 1):i18–i24. doi: 10.1136/gutjnl-2012-302085.
    1. Lampertico P, Vigano M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology. 2013;57:890–896. doi: 10.1002/hep.25749.
    1. Cheng L, Sun X, Tan S, et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in HBeAg seropositive chronic hepatitis B patients. Hepatol Res. 2014;44(9):1000–1007. doi: 10.1111/hepr.12284.
    1. Tseng TC, Yu ML, Liu CJ, et al. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-alpha-2a therapy. Antivir Ther 2011;16:629–637 (ref 310)
    1. Tseng TC, Kao JH, Chen DS. Peginterferon alfa in the treatment of chronic hepatitis B. Expert Opin Biol Ther. 2014. doi:10.1517/14712598.2014.907784
    1. Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679–693.
    1. Ghany M, Feld J, Zhao X, et al. Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1027–1035.
    1. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, et al. Long-termentecavir therapy results in the reversal of fibrosis/cirrhosis and continuedhistological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893. doi: 10.1002/hep.23785.
    1. Papatheodoridis GV, Lampertico P, Manolakopoulos S, Lok A. Incidence ofhepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. J Hepatol. 2010;53:348–356. doi: 10.1016/j.jhep.2010.02.035.
    1. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, et al. Virological suppression does notprevent the development of hepatocellular carcinoma in HBeAg-negativechronic hepatitis B patients with cirrhosis receiving oral antiviral(s)starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut. 2011;60:1109–1116. doi: 10.1136/gut.2010.221846.
    1. Miquel M, Núñez Ó, Trapero-Marugán M, Díaz-Sánchez A, Jiménez M, Arenas J, et al. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhoticpatients in clinical practice. Ann Hepatol. 2013;12(2):205–212.
    1. Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viralcirrhotic patients: comparison between compensated and decompensated cirrhosis. Am J Gastroenterol. 2014;109(8):1223–1233. doi: 10.1038/ajg.2014.145.
    1. Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol. 1990;12(5):562–568. doi: 10.1097/00004836-199010000-00015.
    1. Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92:1839–1843.
    1. Lok AS, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–188.
    1. Chan HL, Hui Y, Leung NW, Ching JY, Chan FK, Sung JJ. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. Am J Gastroenterol. 2000;95:3547–3551.
    1. Sung JJ, Chan HL, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat. 2002;9:229–234. doi: 10.1046/j.1365-2893.2002.00352.x.
    1. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89:732–735.
    1. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology. 1987;7:20–23. doi: 10.1002/hep.1840070106.
    1. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol. 1990;10:29–34. doi: 10.1016/0168-8278(90)90069-4.
    1. Wong VW, Chan HL. Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease. J Gastroenterol Hepatol. 2009;24(7):1179–1186. doi: 10.1111/j.1440-1746.2009.05924.x.
    1. Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology. 2003;38:1075–1086. doi: 10.1053/jhep.2003.50453.
    1. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA. 1991;88:4186–4190. doi: 10.1073/pnas.88.10.4186.
    1. Oketani M, Oketani K, Xiaohong C, Arima T. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. J Med Virol. 1999;58:332–337. doi: 10.1002/(SICI)1096-9071(199908)58:4<332::AID-JMV3>;2-Q.
    1. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120(4):1009–1022. doi: 10.1053/gast.2001.22461.
    1. Gerner P, Lausch E, Friedt M, Tratzmuller R, Spangenberg C, Wirth S. Hepatitis B virus core promoter mutations in children with multiple anti-HBe/HBeAg reactivations result in enhanced promoter activity. J Med Virol. 1999;59:415–423. doi: 10.1002/(SICI)1096-9071(199912)59:4<415::AID-JMV1>;2-M.
    1. Davis GL, Hoofnagle JH. Reactivation of chronic hepatitis B virus infection. Gastroenterology. 1987;92:2028–2031.
    1. Sarin SK, Kumar M, Shrivastava S, Sinha S, Pati NT. Influence of chronic HBV infection on pregnancy: a human model of maternofetal virus host interactions. Gastroenterology. 2011;141(4):1522–1525. doi: 10.1053/j.gastro.2011.08.016.
    1. Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, Chang TH, Chen DS. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B eantigen seroconversion. J Clin Invest. 1992;89:87–96. doi: 10.1172/JCI115590.
    1. Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver failure display “sepsis-like” immune paralysis. J Hepatol. 2005;42:195–201. doi: 10.1016/j.jhep.2004.10.019.
    1. Chu CM, Sheen IS, Liaw YF. The etiology of acute hepatitis in Taiwan: acute hepatitis superimposed upon HBsAg carrier state as the main etiology of acute hepatitis in areas with high HBsAg carrier rate. Infection. 1988;16:233–237. doi: 10.1007/BF01650760.
    1. Gerlich WH, Uy A, Lambrecht F, et al. Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. J Clin Microbiol. 1986;24:288–293.
    1. Kusumoto K, Yatsuhashi H, Nakao R, et al. Detection of HBV core promoter and precore mutations helps distinguish flares of chronic hepatitis from acute hepatitis B. J Gastroenterol Hepatol. 2008;23:790–793. doi: 10.1111/j.1440-1746.2008.05391.x.
    1. Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis. 2003;36:979–984. doi: 10.1086/374226.
    1. Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010;8(6):541–545. doi: 10.1016/j.cgh.2010.02.023.
    1. Tsubota A, Arase Y, Suzuki Y, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2005;20:426–432 (ref 383)
    1. Mori N, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, et al. Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection. J Gastroenterol. 2012;47(9):1022–1029. doi: 10.1007/s00535-012-0561-8.
    1. Sun QF, Ding JG, Xu DZ, et al. Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. J Viral Hepat 2009;16:464–470 (ref 377)
    1. Lai J, Lin CS, Yang L, Chen SR, Zhang YQ, Ke WM. Pretreatment HBsAg level and an early decrease in MELD score predict prognosis to lamivudine treatment for HBeAg negative acute-on-chronic liver failure. Clin Res Hepatol Gastroenterol. 2014;38(3):331–336. doi: 10.1016/j.clinre.2013.10.012.
    1. Lee WC, Chou HS, Wu TJ, Lee CS, Lee CF, Chan KM. Indicators and outcome of liver transplantation in acute liver decompensation after flares of hepatitis B. J Viral Hepat. 2011;18:193–199. doi: 10.1111/j.1365-2893.2010.01295.x.
    1. Sun LJ, Yu JW, Zhao YH, Kang P, Li SC. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure. J Gastroenterol Hepatol. 2010;25(3):583–590. doi: 10.1111/j.1440-1746.2009.06089.x.
    1. Lai J, Yan Y, Mai L, Zheng YB, Gan WQ, Ke WM. Short-term entecavir versus lamivudine therapy for HBeAg-negative patients with acute-on-chronic hepatitis B liver failure. Hepatobiliary Pancreat Dis Int. 2013;12(2):154–159. doi: 10.1016/S1499-3872(13)60025-9.
    1. Zheng MH, Shi KQ, Fan YC, et al. A model to determine 3-month mortality risk in patients with acute-on-chronic hepatitis B liver failure. Clin Gastroenterol Hepatol. 2011;9:351–356. doi: 10.1016/j.cgh.2010.12.027.
    1. Yang WB, Chen EQ, Bi HX, Bai L, Chen XB, Feng P, Tang H. Different models in predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Ann Hepatol. 2012;11(3):311–319.
    1. Duseja A, Choudhary NS, Gupta S, Dhiman RK, Chawla YK. APACHE II score is superior to SOFA, CTP and MELD in predicting the short term mortality in patients with acute-on-chronic liver failure (ACLF) J Dig Dis. 2013;14(9):484–490. doi: 10.1111/1751-2980.12074.
    1. Levesque E, Hoti E, Azoulay D, Ichaï P, Habouchi H, Castaing D, et al. Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol. 2012;56:95–102. doi: 10.1016/j.jhep.2011.06.024.
    1. Tsubota A, Arase Y, Saitoh S, et al. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am J Gastroenterol. 2001;96:557–562. doi: 10.1111/j.1572-0241.2001.03559.x.
    1. Chan HL, Tsang SW, Hui Y, Leung NW, Chan FK, Sung JJ. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice. J Viral Hepat. 2002;9:424–428. doi: 10.1046/j.1365-2893.2002.00385.x.
    1. Tsang SW, Chan HL, Leung NW, et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment Pharmacol Ther. 2001;15:1737–1744. doi: 10.1046/j.1365-2036.2001.01107.x.
    1. Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322–327. doi: 10.1016/S0168-8278(02)00419-1.
    1. Xie F, Yan L, Lu J, Zheng T, Shi C, et al. Effects of nucleoside analogue on patients with chronic hepatitis B-associated liver failure: meta-analysis. PLoS One. 2013;8(1):e54773. doi: 10.1371/journal.pone.0054773.
    1. Shi Y, He J, Wei W, Huang J, Yang Y, Sheng J, Liang Yu, Chen Z, Jia H. The efficacy and safety of nucleos(t)ide analogues in the treatment of HBV-related acute-on-chronicliver failure: a meta-analysis. Ann Hepat. 2013;12(3):364–372.
    1. Chen J, Han J-H, Liu C, Ren-He Yu, Li F-Z, Li Q-F, Gong G-Z. Short-term Entecavir therapy of chronic severe hepatitis B. Hepatobiliary Pancreat Dis Int. 2009;8:261–266.
    1. Wong VW, Wong GL, Yiu KK, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 2011;54:236–242. doi: 10.1016/j.jhep.2010.06.043.
    1. Tsai WL, Chiang PH, Chan HH, Lin HS, Lai KH, Cheng JS, et al. Early entecavir treatment for chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother. 2014;58(4):1918–1921. doi: 10.1128/AAC.02400-13.
    1. Kanda T, Shinozaki M, Kamezaki H, Wu S, Nakamoto S, Arai M, et al. Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B. Int J Med Sci. 2012;9(1):27–32. doi: 10.7150/ijms.9.27.
    1. Liu C, Ye J, Jia H, Zhang M, Han H, Chen F, et al. Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp Ther Med. 2013;5:545–548.
    1. Chen T, He Y, Liu X, Yan Z, Wang K, Liu H, Zhang S, Zhao Y. Nucleoside analogues improve the short-term and long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure. Clin Exp Med. 2012;12(3):159–164. doi: 10.1007/s10238-011-0160-7.
    1. Zhang Y, Hu XY, Zhong S, Yang F, Zhou TY, Chen G, Wang YY, Luo JX. Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. World J Gastroenterol. 2014;20(16):4745–4752. doi: 10.3748/wjg.v20.i16.4745.
    1. Chen Y-C, Hsu C-W, Chang M-Y, Yeh C-T. On-treatment mortality predictors in chronic hepatitis B patients experiencing severe acute exacerbation: a prospective observational study. BMC Res Notes. 2013;6:349. doi: 10.1186/1756-0500-6-349.
    1. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–780. doi: 10.1002/hep.24109.
    1. Jindal A, Kumar M, Sarin SK. A prospective randomized controlled study to compare the efficacy of combined tenofovir plus telbuvidine versus tenofovir alone in patients with spontaneous reactivation of hepatitis B. J Viral Hepatitis 2015;22(Supplement S2):141–142
    1. Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, et al. Liver transplantation for acute-on-chronic liver failure. Hepatol Int. 2009;3(4):571–581. doi: 10.1007/s12072-009-9148-8.
    1. Chok K, Chan SC, Fung JY, Cheung TT, Chan AC, Fan ST, et al. Survival outcomes of right-lobe living donor transplantation for patients with high model for end stage liver disease scores. Hepatobiliary Pancreat Dis Int. 2013;12(3):256–262. doi: 10.1016/S1499-3872(13)60042-9.
    1. Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, et al. Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(3):505–512. doi: 10.1053/j.gastro.2011.11.027.
    1. Kribben A, Gerken G, Haag S, Herget-Rosenthal S, Treichel U, Betz C, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology. 2012;142(4):782–789. doi: 10.1053/j.gastro.2011.12.056.
    1. Zhang XQ, Jiang L, You JP, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46–53. doi: 10.1111/j.1872-034X.2010.00740.x.
    1. Yasui S, Fujiwara K, Nakamura M, Miyamura T, Yonemitsu Y, Mikata R, et al. Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B. J Viral Hepat. 2015;22(2):94–102. doi: 10.1111/jvh.12258.
    1. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–474. doi: 10.1007/s12072-010-9165-7.
    1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(Suppl. 3):S206–S214. doi: 10.1016/S1590-8658(10)60507-5.
    1. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–1133. doi: 10.1016/S0140-6736(81)90585-7.
    1. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159–1172. doi: 10.1111/j.1365-2036.2004.01963.x.
    1. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–690. doi: 10.1111/j.1572-0241.2003.07327.x.
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022. doi: 10.1002/hep.24199.
    1. Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnu L, et al. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol. 2007;102:2448–2457. doi: 10.1111/j.1572-0241.2007.01395.x.
    1. Jung KS, Kim SU, Ahn SH, Park YN, Kim DY, Park JY, et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) Hepatology. 2011;53:885–894. doi: 10.1002/hep.24121.
    1. Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60:339–345. doi: 10.1016/j.jhep.2013.09.029.
    1. Fox AN, Terrault NA. The option of HBIG free prophylaxis against recurrent HBV. J Hepatol. 2012;56:1189–1197. doi: 10.1016/j.jhep.2011.08.026.
    1. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005;11:402–409. doi: 10.1002/lt.20402.
    1. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated withan increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134:1890–1899. doi: 10.1053/j.gastro.2008.02.064.
    1. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329:1842–1847. doi: 10.1056/NEJM199312163292503.
    1. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxisagainst hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011;17:1176–1190. doi: 10.1002/lt.22354.
    1. Rao W, Wu X, Xiu D. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis. Transpl Int. 2009;22:387–394. doi: 10.1111/j.1432-2277.2008.00784.x.
    1. Cholongitas E, Papatheodoridis GV. High geneticbarrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant. 2013;13:353–362. doi: 10.1111/j.1600-6143.2012.04315.x.
    1. Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996;24:1327–1333. doi: 10.1002/hep.510240601.
    1. Roche B, Samuel D. Prevention of hepatitis B virus reinfection in liver transplant recipients. Intervirology. 2014;57:196–201. doi: 10.1159/000360944.
    1. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B followingliver transplantation. Gastroenterology. 2007;132:931–937. doi: 10.1053/j.gastro.2007.01.005.
    1. Di Costanzo GG, Lanza AG, Picciotto FP, et al. Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study. Am J Transplant. 2013;13:348–352. doi: 10.1111/j.1600-6143.2012.04319.x.
    1. Degertekin B, Han SH, Keeffe EB, et al. Impact of virological breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10:1823–1833. doi: 10.1111/j.1600-6143.2010.03046.x.
    1. Buti M, Mas A, Prieto M, et al. A randomized study comparing lamivudine monotherapyafter a short course of hepatitis B immune globulin (HBIg) and lamivudine with longterm lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 2003;38:811–817. doi: 10.1016/S0168-8278(03)00087-4.
    1. Buti M, Mas A, Prieto M, et al. Adherence tolamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitisB virus recurrence. Transplantation. 2007;84:650–654. doi: 10.1097/01.tp.0000277289.23677.0a.
    1. Angus PW, Patterson SJ, Strasser SI, Mc-Caughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology. 2008;48:1460–1466. doi: 10.1002/hep.22524.
    1. Teperman LW, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovirdisoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transpl 2013;19:594–601
    1. Yi NJ, Choi JY, Suh KS, Cho JY, Baik M, Hong G, et al. Post-transplantationsequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol. 2013;48:1401–1410. doi: 10.1007/s00535-013-0761-x.
    1. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 1996;348:1212–1215. doi: 10.1016/S0140-6736(96)04444-3.
    1. Schiff E, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl. 2007;13:349–360. doi: 10.1002/lt.20981.
    1. Gane E, Patterson S, Strasser S, McCaughan G, Angus P. Combination lamivudine plus adefovir without HBIG is safe and effective prophylaxis against HBV recurrence inHBsAg+ liver transplant candidates. Liver Transpl. 2013;19:268–274. doi: 10.1002/lt.23600.
    1. Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013;108:942–948. doi: 10.1038/ajg.2013.111.
    1. Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar A. Living related liver transplantation for hepatitis B-related liverdisease without hepatitis B immune globulin prophylaxis. Liver Transpl. 2013;19:1030–1035. doi: 10.1002/lt.23692.
    1. Ahn J, Cohen SM. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. Hepat Mon. 2011;11:638–645. doi: 10.5812/kowsar.1735143X.1010.
    1. Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology. 2003;38:86–95. doi: 10.1053/jhep.2003.50294.
    1. Lenci I, Tisone G, Di Paolo D, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol. 2011;55:587–593. doi: 10.1016/j.jhep.2010.12.036.
    1. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis. 2012;14:479–487. doi: 10.1111/j.1399-3062.2012.00741.x.
    1. Choudhary NS, Saraf N, Saigal S, Mohanka R, Rastogi A, Goja S, et al. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplanthepatitis B virus prophylaxis? Transpl Infect Dis. 2015;17(3):329–333. doi: 10.1111/tid.12369.
    1. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection—a global challenge. N Engl J Med. 2012;366:1749–1752. doi: 10.1056/NEJMp1201796.
    1. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology. 2009;49:S138–S145. doi: 10.1002/hep.22883.
    1. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. HepatitisB and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593–601. doi: 10.1097/01.aids.0000163936.99401.fe.
    1. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Muñoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liverrelated mortality in the Multicenter Cohort Study (MACS) Lancet. 2002;360:1921–1926. doi: 10.1016/S0140-6736(02)11913-1.
    1. Roca B, Suarez I, Gonzalez J, Garrido M, de la Fuente B, Teira R, et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain. J Infect. 2003;47:117–124. doi: 10.1016/S0163-4453(03)00067-7.
    1. Eskild A, Magnus P, Petersen G, Sohlberg C, Jensen F, Kittelsen P, et al. Hepatitis B antibodies in HIV-infected homosexual men are associated with more rapid progression to AIDS. AIDS. 1992;6:571–574. doi: 10.1097/00002030-199206000-00008.
    1. Scharschmidt BF, Held MJ, Hollander HH, Read AE, Lavine JE, Veereman G, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med. 1992;117:837–838. doi: 10.7326/0003-4819-117-10-837.
    1. Sinicco A, Raiteri R, Sciandra M, Bertone C, Lingua A, Salassa B, et al. Coinfection and superinfection of hepatitis B virus in patients infected with human immunodeficiencyvirus: no evidence of faster progression to AIDS. Scand J Infect Dis. 1997;29:111–115. doi: 10.3109/00365549709035869.
    1. Tsai MS, Chang SY, Lo YC, Yang CJ, Sun HY, Liu WC. Hepatitis B virus (HBV) coinfection accelerates immunological progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. J Infect Dis. 2013;208:1184–1186. doi: 10.1093/infdis/jit299.
    1. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis. 2012;205:185–193. doi: 10.1093/infdis/jir720.
    1. Wandeler G, Gsponer T, Bihl F, Bernasconi E, Cavassini M, Kovari H, et al. Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study. J Infect Dis. 2013;208:1454–1458. doi: 10.1093/infdis/jit351.
    1. Bodsworth NJ, Cooper DA, Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis. 1991;163:1138–1140. doi: 10.1093/infdis/163.5.1138.
    1. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306–1310. doi: 10.1002/hep.510290447.
    1. Sheng WH, Chen MY, Hsieh SM, Hsiao CF, Wang JT, Hung CC, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis. 2004;38:1471–1477. doi: 10.1086/420744.
    1. Hung CC, Wu SM, Lin PH, Sheng WH, Yang ZY, Sun HY, et al. Increasing incidence of recent hepatitis D virus infection in HIV-infected patients in an area hyperendemic for hepatitis B virus infection. Clin Infect Dis. 2014;58:1625–1633. doi: 10.1093/cid/ciu127.
    1. Tuma P, Medrano J, Resino S, Vispo E, Madejon A, Sanchez-Piedra C, et al. Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. Antivir Ther. 2010;15:881–886. doi: 10.3851/IMP1630.
    1. Piroth L, Pol S, Lacombe K, Miailhes P, Rami A, Rey D, et al. Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. J Hepatol. 2010;53:1006–1012. doi: 10.1016/j.jhep.2010.04.041.
    1. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV infected adults. HIV Med. 2008;9:82–88. doi: 10.1111/j.1468-1293.2007.00535.x.
    1. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, Pas SD, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology. 2010;139:1934–1941. doi: 10.1053/j.gastro.2010.08.045.
    1. McMahon M, Jilek B, Brennan T, et al. The HBV drug entecavir —effects on HIV-1replication and resistance. N Engl J Med. 2007;356:2614–2621. doi: 10.1056/NEJMoa067710.
    1. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerasemutations in HIV coinfected patients treated with tenofovir. Antivir Ther. 2005;10:727–734.
    1. Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis. 2008;47:1486–1489. doi: 10.1086/593105.
    1. Martin-Carbonero L, Soriano V. New paradigms for treating hepatitis B in HIV/HBV co-infected patients. J Antimicrob Chemother. 2010;65:379–382. doi: 10.1093/jac/dkp492.
    1. Tuma P, Pineda J, Labarga P, et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther. 2011;16:585–589. doi: 10.3851/IMP1778.
    1. Schirmera P, Wintersb M, Holodniy M. HIV–HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. J Clin Virol. 2011;52:261–264. doi: 10.1016/j.jcv.2011.07.014.
    1. Rivas P, Herrero MD, Puente S, et al. Immunizations in HIV-infected adults. AIDS Rev. 2007;9:173–187.
    1. Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305:1432–1440. doi: 10.1001/jama.2011.351.
    1. Liu CJ, Chen PJ. Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection. World J Gastroenterol. 2014;20:2955–2961. doi: 10.3748/wjg.v20.i11.2955.
    1. Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology. 2004;126:1024–1029. doi: 10.1053/j.gastro.2004.01.011.
    1. Cho LY, Yang JJ, Ko KP, et al. Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer. 2011;128:176–184. doi: 10.1002/ijc.25321.
    1. Huang YT, Jen CL, Yang HI, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 2011;29:3643–3650. doi: 10.1200/JCO.2011.36.2335.
    1. Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-co-infected patients. Hepatology. 2006;43:100–107. doi: 10.1002/hep.20944.
    1. Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009;50:46–55. doi: 10.1002/hep.22951.
    1. Liu CJ, Chen PJ, Lai MY, Kao JH, Jeng YM, Chen DS. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–576. doi: 10.1053/jhep.2003.50096.
    1. Liu CJ, Chuang WL, Lee CM, et al. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504. doi: 10.1053/j.gastro.2008.10.049.
    1. Yu ML, Lee CM, Chen CL, Chuang WL, Lu SN, Liu CH, et al. Sustained HCV.clearance and increased HBsAgseroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. Hepatology. 2013;57:2135–2142. doi: 10.1002/hep.26266.
    1. Potthoff A, Wedemeyer H, Boecher WO, et al. The HEP-NET B/C co-infection trial: a prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. J Hepatol. 2008;49:688–694. doi: 10.1016/j.jhep.2008.03.028.
    1. Liu CJ, Chu YT, Shau WY, et al. Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut. 2014;63:506–514. doi: 10.1136/gutjnl-2012-304370.
    1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85. doi: 10.1016/S0140-6736(10)61931-9.
    1. Yurdaydin C, Idilman R, Bozkaya H, Bozdayi AM. Natural history andtreatment of chronic delta hepatitis. J Viral Hepat. 2010;17:749–756. doi: 10.1111/j.1365-2893.2010.01353.x.
    1. Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. 2013;15:31–38. doi: 10.1007/s11908-012-0307-z.
    1. Castelnau C, Le GF, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta:relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–735. doi: 10.1002/hep.21325.
    1. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Longterm benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–1749. doi: 10.1053/j.gastro.2004.03.017.
    1. Heidrich B, Yurdaydin C, Kabacam G, et al. Long-term followup after Peg-IFNa2a-based therapy of chronic hepatitis delta. J Hepatol. 2013;58:S20. doi: 10.1016/S0168-8278(13)60048-3.
    1. Farci P, Mandas A, Coiana A, et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engl J Med. 1994;330:88–94. doi: 10.1056/NEJM199401133300202.
    1. Lamers MH, Kirgiz OO, Heidrich B, et al. Interferon-alpha for patients with chronic hepatitis delta: a systematic review of randomized clinical trials. Antivir Ther. 2012;17:1029–1037. doi: 10.3851/IMP2306.
    1. Alavian SM, Tabatabaei SV, Behnava B, et al. Standard and pegylated interferon therapy of HDVinfection: a systematic review and meta-analysis. J Res Med Sci. 2012;17:967–974.
    1. Kabacam G, Onder FO, Yakut M, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55(5):645–650. doi: 10.1093/cid/cis459.
    1. Abbas Z, Memon MS, Mithani H, Jafri W, Hamid S, et al. Treatment of chronic hepatitis d patients with pegylated interferon: a real world experience. Antivir Ther. 2014;19(5):463–468. doi: 10.3851/IMP2728.
    1. Abbas Z, Khan MA, Salih M, Jafri W, et al. Interferon alfa for chronic hepatitis D. Cochrane Database Syst Rev 2011;(12):CD006002
    1. Nikongolo S, Ni Y, Lempp FA, et al. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. J Hepatol. 2014;60:723–731. doi: 10.1016/j.jhep.2013.11.022.
    1. Lutgehetmann M, Mancke LV, Volz T, et al. Human chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology. 2012;55:685–694. doi: 10.1002/hep.24758.
    1. Wedemeyer H, Yurdaydin C, Dalekos G, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–331. doi: 10.1056/NEJMoa0912696.
    1. Chen GY, et al. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. J Formos Med Assoc 2013. doi:10.1016/j.jfma.2013.05.011
    1. Mansour W, Ducancelle A, Gal FL, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtrictabine. J Clin Virol. 2010;47(1):97–99. doi: 10.1016/j.jcv.2009.09.027.
    1. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA andvhepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–664. doi: 10.1016/j.jhep.2009.10.036.
    1. CDC. Immunization of health-care personnel: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011;60(RR-7):1–45
    1. CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR-11)1–52
    1. Bell D, Shapiro C, Culver D, Martone W, Curran J, Hughes J. Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model. Infect Agents Dis. 1992;1:263–269.
    1. Bhat M, Ghali P, Deschenes M, Wong P. Hepatitis B and the infected health care worker: public safety at what cost? Can J Gastroenterol. 2012;26(5):257–260.
    1. Schalm S, Buster E. Management of hepatitis B virus infected health care workers based on HBV DNA levels. J Clin Virol. 2003;27:231–234. doi: 10.1016/S1386-6532(03)00158-6.
    1. Prentice M, Flower A, Morgan G, et al. Infection with hepatitis B virus after open heart surgery. BMJ. 1992;304(6829):761–764. doi: 10.1136/bmj.304.6829.761.
    1. Harpaz R, Von Seidlein L, Averhoff F, et al. Transmission ofhepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med. 1996;334:549–554. doi: 10.1056/NEJM199602293340901.
    1. Lettau L, Smith J, Williams D, et al. Transmission of hepatitis B with resultant restriction of surgical practice. JAMA. 1986;255(7):934–937. doi: 10.1001/jama.1986.03370070088032.
    1. Welch J, Tilzey A, Webster M, Noah N, Banatvala J. Hepatitis B infections after gynaecological surgery. Lancet. 1989;333:205–207. doi: 10.1016/S0140-6736(89)91213-0.
    1. Corden S, Ballard A, Ijaz S, et al. HBV DNA levels and transmission of hepatitis B by health care workers. J Clin Virol. 2003;27:52–58. doi: 10.1016/S1386-6532(02)00127-0.
    1. Spijkerman I, van Doorn L, Janssen M, et al. Transmission of hepatitis B virus from a surgeon to his patients during high-risk and low-risk surgical procedures during 4 years. Infect Control Hosp Epidemiol. 2002;23:306–312. doi: 10.1086/502056.
    1. Hasselhorn H, Hofmann F. Transmission of HBV, HCV and HIV by infectious medical personnel—presentation of an overview. Chirurg. 2000;71(4):389–395. doi: 10.1007/s001040051070.
    1. Centers for Disease Control and Prevention (CDC) Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. MMWR Recomm Rep. 2012;61(3):1–12.
    1. Henderson DK, Dembry L, Fishman NO, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus. Infect Control Hosp Epidemiol. 2010;31:203–232. doi: 10.1086/650298.
    1. Buster EH, van der Eijk AA, de Man RA. JanssenHL, Schalm SW: prolonged antiviral therapy for hepatitis B virus-infected health careworkers: a feasible option to prevent work restriction without jeopardizing patient safety. J Viral Hepat. 2007;14:350–354. doi: 10.1111/j.1365-2893.2006.00809.x.
    1. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. BEHoLD AI463022 Study Group: a comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010. doi: 10.1056/NEJMoa051285.
    1. Ceylan B, Yardimci C, Fincanci M, Eren G, Tozalgan U, Muderrisoglu C, et al. Comparison of tenofovir and entecavir in patients with chronic HBV infection. Eur Rev Med Pharmacol Sci. 2013;17:2467–2473.
    1. Gerlich WH. Reduction of infectivity in chronic hepatitis B virus carriers among healthcare providers and pregnant women by antiviral therapy. Intervirology. 2014;57(3–4):202–211. doi: 10.1159/000360949.
    1. Patton H, Tran TT. Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol. 2014;11:402–409. doi: 10.1038/nrgastro.2014.30.
    1. Pan CQ, Lee HM. Antiviral therapy for chronic hepatitis B in pregnancy. Semin Liver Dis. 2013;33:138–146. doi: 10.1055/s-0033-1345718.
    1. Committee APRS. Antiretroviral Pregnancy Registry International. Interim Report for 1 January Through 31 JANUARY 2013. Wilmington, NC: Registry Coordinating Center; 2013 (online). (2012)
    1. Wen WH, Chang MH, Zhao LL, et al. Mother-to-infant transmission of hepatitis B virus infection: significance of maternal viral load and strategies for intervention. J Hepatol 2013;59:24–30 (ref 561)
    1. Kubo A, Shlager L, Marks AR, et al. Prevention of vertical transmission of hepatitis B: an observational study. Ann Intern Med. 2014;160:828–835. doi: 10.7326/M13-2529.
    1. Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:147–159. doi: 10.1097/AOG.0b013e3181e45951.
    1. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2014; 60(Suppl. S1):984A [(AASLD 2014) abstract]
    1. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011;55:1215–1221 (ref 555)
    1. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B Virus. J Hepatol. 2014;61:502–507. doi: 10.1016/j.jhep.2014.04.038.
    1. Pan CQ, Mi LJ, Bunchorntavakul C, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Dig Dis Sci. 2012;57:2423–2429. doi: 10.1007/s10620-012-2187-3.
    1. Zhang H, Pan CQ, Pang Q, et al. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014;60:468–476. doi: 10.1002/hep.27034.
    1. Yu MM, Jiang Q, Ji Y, et al. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. J Clin Virol. 2014;61:55–60. doi: 10.1016/j.jcv.2014.06.005.
    1. Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol. 2013;19:9377–9382. doi: 10.3748/wjg.v19.i48.9377.
    1. Benaboud S, Pruvost A, Coffie PA, et al. Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d’Ivoire, in the ANRS12109 TEmAA Study, step 2. Antimicrob Agents Chemother. 2011;55:1315–1317. doi: 10.1128/AAC.00514-10.
    1. Hill JB, Sheffield JS, Kim MJ, et al. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol. 2002;99:1049–1052. doi: 10.1016/S0029-7844(02)02000-8.
    1. Nguyen V, Tan PK, Greenup AJ, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther. 2014;39:1225–1234. doi: 10.1111/apt.12726.
    1. Pipili C, Cholongitas E, Papatheodoridis G. Nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther. 2014;39(1):35–46. doi: 10.1111/apt.12538.
    1. Brzosko WJ, Krawczynski K, Nazarewicz T, Morzycka M, Nowoslawski A. Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet. 1974;2:477–482. doi: 10.1016/S0140-6736(74)92012-1.
    1. Chan G, Kowdley KV. Extrahepatic manifestations of chronic viral hepatitis. Compr Ther. 1995;21:200–205.
    1. Takekoshi Y, Tanaka M, Miyakawa Y, Yoshizawa H, Takahashi K, Mayumi M. Free, “small” and IgG-associated “large” hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med. 1979;300:814–819. doi: 10.1056/NEJM197904123001502.
    1. Lai KN, Lai FM, Lo ST, Lam CW. IgA nephropathy and membranous nephropathy associated with hepatitis B surface antigenemia. Hum Pathol. 1987;18:411–414. doi: 10.1016/S0046-8177(87)80177-6.
    1. Wang NS, Wu ZL, Zhang YE, Guo MY, Liao LY. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol. 2003;9(9):2004–2008. doi: 10.3748/wjg.v9.i9.2004.
    1. Tang S, Lai FM, Lui YH, Tang CS, Kung NN, Ho YW, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int. 2005;68:1750–1758. doi: 10.1111/j.1523-1755.2005.00591.x.
    1. Shah HH, Patel C, Jhaveri KD. Complete remission of hepatitis B virus-associated nephrotic syndrome from IgA nephropathy following peginterferon therapy. Renal Fail. 2013;35(2):295–298. doi: 10.3109/0886022X.2012.745785.
    1. Zheng X-Y, Wei R-B, Tang L, Li P, Zheng X-D. Meta-analysis of combined therapy for adult hepatitis B virus-associated glomerulonephritis. World J Gastroenterol. 2012;18(8):821–832. doi: 10.3748/wjg.v18.i8.821.
    1. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006;24(5):781–788. doi: 10.1111/j.1365-2036.2006.03041.x.
    1. Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa. Arthritis Rheum. 2010;62(2):616–626. doi: 10.1002/art.27240.
    1. Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7:270–275. doi: 10.1007/s11926-005-0036-5.
    1. Janssen HL, van Zonneveld M, van Nunen AB, Niesters HG, Schalm SW, de Man RA. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol. 2004;16:801–807. doi: 10.1097/01.meg.0000108362.41221.57.
    1. Guillevin L, Mahr A, Cohen P, Larroche C, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. 2004;51(3):482–487. doi: 10.1002/art.20401.
    1. Levo Y, Gorevic PD, Kassab HJ, Zucker-Franklin D, Franklin EC. Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med. 1977;296:1501–1504. doi: 10.1056/NEJM197706302962605.
    1. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med. 1990;150:1051–1054. doi: 10.1001/archinte.1990.00390170087019.
    1. Enomoto M, Nakanishi T, Ishii M, Tamori A, Kawada N. Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med. 2008;149:912–913. doi: 10.7326/0003-4819-149-12-200812160-00019.
    1. D’Amico E, Pace-Palitti V, Di Lembo E, Palazzi C. Successful treatment of hepatitis B virus infection and related cryoglobulinaemic purpura with nuleoside/nucleotide analogues. Clin Exp Rheumatol. 2013;31(1):155.
    1. Hollinger FB, Lau DT. Hepatitis B: the pathway to recovery through treatment. Gastroenterol Clin N Am. 2006;35:425–461. doi: 10.1016/j.gtc.2006.03.002.
    1. Schumacher HR, Gall EP. Arthritis in acute hepatitis and chronic active hepatitis. Pathology of the synovial membrane with evidence for the presence of Australia antigen in synovial membranes. Am J Med. 1974;57:655–664. doi: 10.1016/0002-9343(74)90020-5.
    1. Dogan B. Dermatological manifestations in hepatitis B surface antigen carriers in east region of Turkey. J Eur Acad Dermatol Venereol. 2005;19:323–325. doi: 10.1111/j.1468-3083.2004.01185.x.
    1. Michitaka K, Horiike N, Chen Y, et al. Gianotti–Crosti syndrome caused by acute hepatitis B virus genotype D infection. Intern Med. 2004;43:696–699. doi: 10.2169/internalmedicine.43.696.
    1. Ray G, Ghosh B, Bhattacharyya R. Acute hepatitis B presenting as Guillain–Barré syndrome. Indian J Gastroenterol. 2003;22:228.
    1. Yimam KK, Merriman RB, Frederick RT. A rare case of acute hepatitis B virus infection causing Guillain–Barré syndrome. Gastroenterol Hepatol. 2013;9:121–123.
    1. Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology. 2007;45:1382–1389. doi: 10.1002/hep.21572.
    1. Toyoda H, Kumada T, Tada T, Sone Y, Fujimori M. Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival after concomitant treatment with nucleoside analogues. J Vasc Interv Radiol. 2012;23:317–322. doi: 10.1016/j.jvir.2011.11.012.
    1. Du ZG, Wei YG, Chen KF, Li B. Risk factors associated with early and late recurrence after curative resection of hepatocellular carcinoma: a single institution’s experience with 398 consecutive patients. Hepatobiliary Pancreat Dis Int. 2014;13:153–161. doi: 10.1016/S1499-3872(14)60025-4.
    1. Shin HS, Kim SU, Park JY, Kim do Y, Han KH, Chon CY, et al. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1528–1534. doi: 10.1111/j.1440-1746.2012.07145.x.
    1. Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int. 2013;33:595–604. doi: 10.1111/liv.12112.
    1. Yang T, Lu JH, Zhai J, Lin C, Yang GS, Zhao RH, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38:683–691. doi: 10.1016/j.ejso.2012.04.010.
    1. von Sengbusch A, Gassmann P, Fisch KM, Enns A, Nicolson GL, Haier J. Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids. Am J Pathol. 2005;166:585–596. doi: 10.1016/S0002-9440(10)62280-8.
    1. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, Lee PC, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. J Hepatol. 2009;51:890–897. doi: 10.1016/j.jhep.2009.07.009.
    1. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008;103:1663–1673. doi: 10.1111/j.1572-0241.2008.01872.x.
    1. Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257:490–505. doi: 10.1097/SLA.0b013e318262b218.
    1. Wei Q, Xu X, Ling Q, Zheng S. Indefinite antiviral therapy may be required after surgical resection for hepatocellular carcinoma complicating chronic hepatitis B. J Res Med Sci. 2013;18:726–730.
    1. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308:1906–1914. doi: 10.1001/2012.jama.11975.
    1. Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33:1104–1112. doi: 10.1111/j.1365-2036.2011.04634.x.
    1. Qu LS, Liu JX, Kuai XL, Xu ZF, Jin F, Zhou GX. Significance of viral status on recurrence of hepatitis B-related hepatocellular carcinoma after curative therapy: a meta-analysis. Hepatol Res. 2014;44:750–760. doi: 10.1111/hepr.12172.
    1. Zhou Y, Zhang Z, Zhao Y, Wu L, Li B. Antiviral therapy decreases recurrence of hepatitis B virus-related hepatocellular carcinoma after curative resection: a meta-analysis. World J Surg. 2014;38(9):2395–2402. doi: 10.1007/s00268-014-2586-z.
    1. Ke Y, Wang L, Li LQ, Zhong JH. Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection. World J Hepatol. 2014;6(9):652–659. doi: 10.4254/wjh.v6.i9.652.
    1. Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, et al. Antiviral therapy improves post-hepatectomy survival in patients with hepatitis B virus-related hepatocellular carcinoma: a prospective-retrospective study. Aliment Pharmacol Ther. 2015;41(2):199–208. doi: 10.1111/apt.13034.
    1. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009;96:975–981. doi: 10.1002/bjs.6731.
    1. Lau WY, Lai EC, Lau SH. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2009;8:124–133.
    1. Zhang W, Song TQ, Zhang T, Wu Q, Kong DL, Li Q, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125–1134.
    1. Xiao X, Zhenhua T, Wang B, Ling Q, Zhang L, Zhou L, et al. A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int. 2011;31:1477–1484. doi: 10.1111/j.1478-3231.2011.02500.x.
    1. Zheng S, Chen Y, Liang T, Anwei L, Wang W, Shen Y, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006;12(3):253–258. doi: 10.1002/lt.20701.
    1. Hu TH, Chen CL, Lin CC, et al. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation. Transplantation. 2014;97(Suppl 8):S53–S59. doi: 10.1097/01.tp.0000446278.43804.f9.
    1. U.N. General Assembly Document A/RES/44/25 (12 December 1989)
    1. Ni YH. Natural history of hepatitis B virus infection: pediatric perspective. J Gastroenterol. 2011;46:1–8. doi: 10.1007/s00535-010-0304-7.
    1. Corte CD, Nobili V, Comparcola D, Cainelli F, Vento S. Management of chronic hepatitis B in children: an unresolved issue. J Gastroenterol Hepatol 2014;29:912–919 (ref 634)
    1. Elisofon SA, Jonas MM. Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis. 2006;10:133–148. doi: 10.1016/j.cld.2005.10.005.
    1. Hsu HY, Chang MH, Chen DS, Lee CY, Sung JL. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol. 1986;18:301–307. doi: 10.1002/jmv.1890180402.
    1. Bortolotti F, Cadrobbi P, Crivellaro C, Bertaggia A, Realdi G, Alberti A. Chronic hepatitis type B in childhood: longitudinal study of 35 cases. Gut. 1981;22:499–504. doi: 10.1136/gut.22.6.499.
    1. Bortolotti F, Cadrobbi P, Crivellaro C, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B infection in childhood. Gastroenterology. 1990;99:805–810.
    1. Iorio R, Giannattasio A, Cirillo F, D’Alessandro L, Vegnente A. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis. 2007;45:943–949. doi: 10.1086/521864.
    1. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology. 2006;43:556–562. doi: 10.1002/hep.21077.
    1. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis. 2002;186:295–301. doi: 10.1086/341508.
    1. Wen W-H, Chang M-H, Hsu H-Y, Ni Y-H, Chen H-L. The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection. J Pediatr. 2004;144:397–399. doi: 10.1016/j.jpeds.2003.11.022.
    1. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expertpanel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Hepatol. 2013;59(4):814–829. doi: 10.1016/j.jhep.2013.05.016.
    1. Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virological response tolamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004;23:441–445. doi: 10.1097/01.inf.0000126412.93562.f5.
    1. Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988–995 (ref 629)
    1. Narkewicz MR, Smith D, Silverman A, Vierling J, Sokol RJ. Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment. J Pediatr. 1995;127:815–818. doi: 10.1016/S0022-3476(95)70181-8.
    1. Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr. 2004;145:340–345. doi: 10.1016/j.jpeds.2004.05.046.
    1. Bortolotti F, Jara P, Barbera C, et al. Long-term effect of alpha interferon in children with chronic hepatitis B. Gut. 2000;46:715–718. doi: 10.1136/gut.46.5.715.
    1. Vo Thi Diem H, Bourgois A, Bontems P, et al. Chronic hepatitis Binfection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr. 2005;40:141–145. doi: 10.1097/00005176-200502000-00011.
    1. Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudinein children with chronic hepatitis B. N Engl J Med. 2002;346:1706–1713. doi: 10.1056/NEJMoa012452.
    1. Hagmann S, Chung M, Rochford G, et al. Response to lamivudine in children with chronic hepatitis B virus infection. Clin Infect Dis. 2003;37:1434–1440. doi: 10.1086/378739.
    1. Hartman C, Berkowitz D, Shouval D, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J. 2003;22:224–228.
    1. Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 2008;47:1863–1871. doi: 10.1002/hep.22250.
    1. Jonas MM, Kelly D, Pollack H, et al. Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronichepatitis B infection. Pediatr Infect Dis J. 2012;31:578–582. doi: 10.1097/INF.0b013e318255ffe7.
    1. Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology. 2012;56:2018–2026. doi: 10.1002/hep.25818.
    1. Murray JM, Wieland SF, Purcell RH, et al. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA. 2005;102:17780–17785. doi: 10.1073/pnas.0508913102.
    1. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–1108. doi: 10.1038/nm1096-1104.
    1. Keating SM, Heitman JD, Wu S, Deng X, Stramer SL, Kuhns MC, et al. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. J Infect Dis. 2014;209(6):845–854. doi: 10.1093/infdis/jit563.
    1. Whalley SA, Murray JM, Brown D, et al. Kinetics of acute hepatitis B virus infection in humans. J Exp Med. 2001;193:847–854. doi: 10.1084/jem.193.7.847.
    1. Chulanov VP, Shipulin GA, Schaefer S, et al. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol. 2003;69:313–323. doi: 10.1002/jmv.10291.
    1. Gerlich W, Stamm B, Thomssen R. Prognostic significance of quantitative HBsAg determination in acute hepatitis B. Partial report of a cooperative clinical study of the DFG-focus of “virus hepatitis”. Verh Dtsch Ges Inn Med. 1977;83:554–557.
    1. Maruyama T, McLauchlan A, Lino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis infection revisited. J Clin Invest. 1993;91:2586–2595. doi: 10.1172/JCI116497.
    1. Kunnathuparambil SG, Vinayakumar KR, Varma MR, Thomas R, Narayanan P, Sreesh S. Bilirubin, aspartate aminotransferase and platelet count score: a novel score for differentiating patients with chronic hepatitis B with acute flare from acute hepatitis B. Ann Gastroenterol. 2014;27(1):60–64.
    1. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92(6):1844–1850.
    1. Ito K, Yotsuyanagi H, Yatsuhashi H, Karino Y, Takikawa Y, Saito T, et al. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology. 2014;59(1):89–97. doi: 10.1002/hep.26635.
    1. Yotsuyanagi H, Ito K, Yamada N, Takahashi H, Okuse C, Yasuda K, et al. High levels of hepatitis B virus after the onset of disease lead to chronic infection in patients with acute hepatitis B. Clin Infect Dis. 2013;57(7):935–942. doi: 10.1093/cid/cit348.
    1. Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 2004;24:547–551. doi: 10.1111/j.1478-3231.2004.0983.x.
    1. Kumar M, Satapathy S, Monga R, et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology. 2007;45:97–101. doi: 10.1002/hep.21486.
    1. Yu JW, Sun LJ, Zhao YH, Kang P, Li SC. The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci. 2010;55:775–783. doi: 10.1007/s10620-009-1060-5.
    1. Tillmann HL, Hadem J, Leifeld L, et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat. 2006;13:256–263. doi: 10.1111/j.1365-2893.2005.00695.x.
    1. Miyake Y, Iwasaki Y, Takaki A, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008;47:1293–1299. doi: 10.2169/internalmedicine.47.1061.
    1. Yu JW, Sun LJ, Yan BZ, Kang P, Zhao YH. Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int. 2011;31(4):499–506. doi: 10.1111/j.1478-3231.2011.02450.x.
    1. Jochum C, Gieseler RK, Gawlista I, et al. Hepatitis B associated acute liver failure: immediate treatment with entecavir inhibits hepatitis B virus replication and potentially its sequelae. Digestion. 2009;80:235–240. doi: 10.1159/000236009.
    1. Girke J, Wedemeyer H, Wiegand J, Manns MP, Tillmann HL. Acute hepatitis B: is antiviral therapy indicated? Two case reports. Dtsch Med Wochenschr. 2008;133:1178–1182. doi: 10.1055/s-2008-1077235.
    1. Casals-Seoane F, Arberas-Díez B, García-Buey L. Tenofovir treatment of the severe acute hepatitis B. Rev Esp Enferm Dig. 2013;105(1):57–58. doi: 10.4321/S1130-01082013000100015.
    1. Gerada J, Borg E, Formosa D, Magro R, Pocock J. Tenofovir as rescue therapy following clinical failure to Lamivudine in severe acute hepatitis B. Mediterr J Hematol Infect Dis. 2013;5(1):e2013035. doi: 10.4084/mjhid.2013.035.
    1. Lisotti A, Eusebi LH, Festi D, Bazzoli F, Mazzella G. Treatment with telbivudine for fulminant hepatitis B. J Dig Dis. 2013;14(11):619–621.
    1. Yeo W, Chan HL. Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol. 2013;28:31–37. doi: 10.1111/j.1440-1746.2012.07280.x.
    1. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–1749. doi: 10.1053/j.gastro.2003.09.026.
    1. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–853. doi: 10.1002/hep.22106.
    1. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–528. doi: 10.7326/0003-4819-148-7-200804010-00008.
    1. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2008;28:28–38. doi: 10.1111/j.1478-3231.2007.01618.x.
    1. Shiah HS, Chen CY, Dai CY, Hsiao CF, Lin YJ, Su WC, et al. Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2013;37:62–73. doi: 10.1111/apt.12132.
    1. Teplinsky E, Cheung D, Weisberg I, Jacobs RE, Wolff M, Park J, et al. Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literature. Breast Cancer Res Treat. 2013;141:167–172. doi: 10.1007/s10549-013-2681-0.
    1. Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology. 2011;54:1199–1207. doi: 10.1002/hep.24529.
    1. Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ transplantation other than liver. J Hepatol. 2011;55:474–482. doi: 10.1016/j.jhep.2011.01.003.
    1. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013;16:527–531. doi: 10.1111/1756-185X.12154.
    1. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–1029. doi: 10.1007/s10067-010-1523-2.
    1. López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol. 2013;19:1342–1348. doi: 10.3748/wjg.v19.i9.1342.
    1. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetic and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68. doi: 10.1053/j.gastro.2006.04.015.
    1. Yamagata M, Murohisa T, Tsuchida K, Okamoto Y, Tsunoda S, Nakamura M, et al. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab. Leuk Lymphoma. 2007;48:431–433. doi: 10.1080/10428190601059704.
    1. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol. 2006;155:1053–1056. doi: 10.1111/j.1365-2133.2006.07451.x.
    1. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611. doi: 10.1200/JCO.2008.18.0182.
    1. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010;85:243–250. doi: 10.1111/j.1600-0609.2010.01474.x.
    1. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011;90:1219–1223. doi: 10.1007/s00277-011-1241-0.
    1. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092–2100. doi: 10.1002/hep.26718.
    1. Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–3743. doi: 10.1200/JCO.2014.56.7081.
    1. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765–2772. doi: 10.1200/JCO.2012.48.5938.
    1. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2013;31:118–121.
    1. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viralhepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712. doi: 10.1111/j.1365-2141.2006.06465.x.
    1. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007;39:397–408. doi: 10.1016/j.dld.2006.12.017.
    1. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection—the German guideline. Z Gastroenterol. 2011;49:871–930. doi: 10.1055/s-0031-1273462.
    1. Vigano M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoieticSCT. Bone Marrow Transplant. 2011;46:125–131. doi: 10.1038/bmt.2010.70.
    1. Stolz M, Tinguely C, Fontana S, Niederhauser C. Hepatitis B virus DNA viral load determination in hepatitis B surface antigen-negative Swiss blood donors. Transfusion. 2014;54(11):2961–2967. doi: 10.1111/trf.12694.
    1. Lin HJ, Lai CL, Lau JY, Chung HT, Lauder IJ, Fong MW. Evidence for intrafamilial transmission of hepatitis B virus from sequence analysis of mutant HBV DNAs in two Chinese families. Lancet. 1990;336:208–212. doi: 10.1016/0140-6736(90)91735-S.
    1. Stevens CE, Toy PT, Tong MJ, Taylor PE, Vyas GN, Nair PV, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive–active immunization. JAMA. 1985;253:1740–1745. doi: 10.1001/jama.1985.03350360066020.
    1. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virological factors associated with failure to passive–active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012;19:e18–e25. doi: 10.1111/j.1365-2893.2011.01492.x.
    1. Singh AE, Plitt SS, Osiowy C, Surynicz K, Kouadjo E, Preiksaitis J, et al. Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat. 2011;18:468–473. doi: 10.1111/j.1365-2893.2010.01333.x.
    1. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008;26:6587–6591. doi: 10.1016/j.vaccine.2008.09.034.
    1. Kumar M, Sarin SK. Viral hepatitis eradication in India by 2080—gaps, challenges and targets. Indian J Med Res. 2014;140(1):1–4.
    1. Yao GB. Importance of perinatal versus horizontal transmission of hepatitis B virus infection in China. Gut. 1996;38:S39–S42. doi: 10.1136/gut.38.Suppl_2.S39.
    1. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009;51:798–809. doi: 10.1016/j.jhep.2009.05.020.
    1. Yotsuyanagi H, Yasuda K, Iino S, et al. Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology. 1998;27:1377–1382. doi: 10.1002/hep.510270526.
    1. Yuki N, Nagaoka T, Yamashiro M, et al. Long-term histological and virological outcomes of acute self-limited hepatitis B. Hepatology. 2003;37:1172–1179. doi: 10.1053/jhep.2003.50171.
    1. Yuen MF, Wong DK, Fung J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192–1199. doi: 10.1053/j.gastro.2008.07.008.
    1. Morales-Romero J, Vargas G, García-Román R. Occult HBV infection: a faceless enemy in liver cancer development. Viruses. 2014;6:1590–1611. doi: 10.3390/v6041590.
    1. Song EY, Yun YM, Park MH, Seo DH. Prevalence of occult hepatitis B virus infection in a general adult population in Korea. Intervirology. 2009;52:57–62. doi: 10.1159/000214633.
    1. Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatitis B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion. 2007;47:74–79. doi: 10.1111/j.1537-2995.2007.01066.x.
    1. Yuen MF, Lee CK, Wong DK, et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut. 2010;59:1389–1393. doi: 10.1136/gut.2010.209148.
    1. Reesink HW, Engelfriet CP, Henn G, et al. Occult hepatitis B infection in blood donors. Vox Sang. 2008;94:153–166. doi: 10.1111/j.1423-0410.2008.01017.x.
    1. Minuk GY, Sun DF, Uhanova J, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol. 2005;42:480–485. doi: 10.1016/j.jhep.2004.11.037.
    1. Yamamoto K, Horikita M, Tsuda F, et al. Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol. 1994;68:2671–2676.
    1. Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology. 2007;45:277–285. doi: 10.1002/hep.21529.
    1. Huang FY, Wong DK, Seto WK, et al. Sequence variations of full-length hepatitis B virus genomes in Chinese patients with HBsAg-negative hepatitis B infection. PLoS One 2014;9:e99028 (ref 715)
    1. Wong DK, Huang FY, Lai CL, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogeniccause of hepatocellular carcinoma. Hepatology. 2011;54:829–836. doi: 10.1002/hep.24551.
    1. Candotti D, Lin CK, Belkhiri D, et al. Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence. Gut. 2012;61:1744–1753. doi: 10.1136/gutjnl-2011-301281.
    1. El Chaar M, Candotti D, Crowther RA, Allain JP. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology. 2010;52:1600–1610. doi: 10.1002/hep.23886.
    1. Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. Hepatology. 2005;42:93–103. doi: 10.1002/hep.20748.
    1. Bes M, Vargas V, Piron M, et al. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol. 2012;56:765–774. doi: 10.1016/j.jhep.2011.11.011.
    1. Wong DK, Watanabe T, Tanaka Y, et al. Role of HLA-DP polymorphisms on chronicity and disease activity of hepatitis B infection in Southern Chinese. PLoS One. 2013;8:e66920. doi: 10.1371/journal.pone.0066920.
    1. Lam YF, Wong DK, Seto WK, et al. HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. J Gastroenterol Hepatol. 2014;29:533–539. doi: 10.1111/jgh.12378.
    1. Seto WK, Wong DK, Kopaniszen M, et al. HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B. Clin Infect Dis. 2013;56:1695–1703. doi: 10.1093/cid/cit121.
    1. Mosley JW, Stevens CE, Aach RD, et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion. 1995;35:5–12. doi: 10.1046/j.1537-2995.1995.35195090661.x.
    1. Satake M, Taira R, Yugi H, et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007;47:1197–1205. doi: 10.1111/j.1537-2995.2007.01276.x.
    1. Fung J, Lai CL, Chan SC, et al. Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. Am J Gastroenterol. 2010;105:1116–1122. doi: 10.1038/ajg.2009.665.
    1. Wong DK, Fung J, Lee CK, et al. Hepatitis B virus serological and virological activities in blood donors with occult hepatitis B. Hepatol Int. 2014;8(Suppl. 1):S149.
    1. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231–240. doi: 10.1111/j.1478-3231.2011.02481.x.
    1. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely “occult”? Hepatology. 2001;34:194–203. doi: 10.1053/jhep.2001.25172.
    1. Alavian SM, Miri SM, Hollinger FB, Jazayeri SM. Occult hepatitis B (OBH) in clinical settings. Hepat Mon. 2012;12:e6126.
    1. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med. 1981;305:1067–1073. doi: 10.1056/NEJM198110293051807.
    1. Yotsuyanagi H, Shintani Y, Moriya K, et al. Virological analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. J Infect Dis. 2000;181:1920–1928. doi: 10.1086/315512.
    1. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. J Viral Hepat. 2009;16:437–443. doi: 10.1111/j.1365-2893.2009.01085.x.
    1. Covolo L, Pollicino T, Raimondo G, Donato F. Occult hepatitis B virus and the risk for chronic liver disease: a meta-analysis. Dig Liver Dis. 2013;45:238–244. doi: 10.1016/j.dld.2012.09.021.
    1. Bläckberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol. 2000;33:992–997. doi: 10.1016/S0168-8278(00)80134-8.
    1. Bréchot C, Gozuacik D, Murakami Y, Paterlini-Bréchot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) Semin Cancer Biol. 2000;10:211–231. doi: 10.1006/scbi.2000.0321.
    1. Cougot D, Neuveut C, Buendia MA. HBV induced carcinogenesis. J Clin Virol. 2005;34(Suppl. 1):S75–S78. doi: 10.1016/S1386-6532(05)80014-9.
    1. Bertoletti A, Rivino L. Hepatitis B: future curative strategies. Curr Opin Infect Dis. 2014;27(6):528–534. doi: 10.1097/QCO.0000000000000110.
    1. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptorfor human hepatitis B and D virus. Elife. 2012;1:e00049. doi: 10.7554/eLife.00049.
    1. Iwamoto M, Watashi K, Tsukuda S, et al. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. BiochemBiophys Res Commun. 2014;443:808–813. doi: 10.1016/j.bbrc.2013.12.052.
    1. Gripon P, Cannie I, Urban S. Efficientinhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol. 2005;79:1613–1622. doi: 10.1128/JVI.79.3.1613-1622.2005.
    1. Volz T, Allweiss L, MBarek MB, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013;58:861–867. doi: 10.1016/j.jhep.2012.12.008.
    1. Lucifora J, Esser K, Protzer U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res. 2013;97:195–197. doi: 10.1016/j.antiviral.2012.12.008.
    1. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014;343:1221–1228. doi: 10.1126/science.1243462.
    1. Chen J, Zhang W, Lin J, et al. An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. Mol Ther. 2013;22:303–311. doi: 10.1038/mt.2013.212.
    1. Wooddell CI, Rozema DB, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther. 2013;21:973–985. doi: 10.1038/mt.2013.31.
    1. Wu GY, Zheng XJ, Yin CC, et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother. 2008;20:458–467. doi: 10.1179/joc.2008.20.4.458.
    1. Wang XY, Wei ZM, Wu GY, et al. In vitro inhibition of HBV replication by a novel compound, GLS4, and its efficacy against adefovir–dipivoxil-resistant HBV mutations. Antivir Ther. 2012;17:793–803. doi: 10.3851/IMP2152.
    1. . (Accessed 27 Jan 2015)
    1. Hu Y, Cheng X, Cao F, Huang A, Tavis JE. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity. Antiviral Res. 2013;99:221–229. doi: 10.1016/j.antiviral.2013.06.007.
    1. Baltayiannis G, Karayiannis P. Treatment options beyond IFNα and NAs for chronic HBV infection: expectations for tomorrow. J Viral Hepat. 2014;21(11):753–761. doi: 10.1111/jvh.12307.
    1. Maini MK, Schurich A. The molecular basis of the failed immune response in chronic HBV: therapeutic implications. J Hepatol. 2010;52:616–619. doi: 10.1016/j.jhep.2009.12.017.
    1. Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long term effective treatment with nucleos(t)ide analogues. Gastroenterology. 2012;143(4):963–973. doi: 10.1053/j.gastro.2012.07.014.
    1. Buchmann P, Dembek C, Kuklick L, et al. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice. Vaccine. 2013;31:1197–1203. doi: 10.1016/j.vaccine.2012.12.074.
    1. King TH, Kemmler CB, Guo Z, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One. 2014;9:e101904. doi: 10.1371/journal.pone.0101904.
    1. Xu DZ, Wang XY, Shen XL, et al. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013;59:450–456. doi: 10.1016/j.jhep.2013.05.003.
    1. Huang LR, Wohlleber D, Reisinger F, et al. Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+ T cells and successful immunotherapy against chronic viral liver infection. Nat Immunol. 2013;14:574–583. doi: 10.1038/ni.2573.
    1. Isogawa M, Chung J, Murata Y, et al. CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog. 2013;9:e1003490. doi: 10.1371/journal.ppat.1003490.
    1. Krebs K, Böttinger N, Huang LR, et al. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology. 2013;145:456–465. doi: 10.1053/j.gastro.2013.04.047.
    1. Gehring AJ, Xue S-A, Ho ZZ, et al. Engineering virus-specific T cells that target HBV-infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011;55:103–110. doi: 10.1016/j.jhep.2010.10.025.
    1. Zoulim F, Luangsay S, Durantel D. Targeting innate immunity: a new step in the development of combination therapy for chronic hepatitis B. Gastroenterology. 2013;144:1342–1344. doi: 10.1053/j.gastro.2013.04.028.
    1. Ji C, Sastry KSR, Tiefenthaler G, et al. Targeted delivery of interferon-a to hepatitis B virus-infected cells using T-cell receptor-like antibodies. Hepatology. 2012;56:2027–2038. doi: 10.1002/hep.25875.
    1. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of toll-like receptor-7, induces prolonged suppression of hepatitis b virus in chronically infected chimpanzees. Gastroenterology. 2013;144(7):1508.e1-10–1517.e1-10. doi: 10.1053/j.gastro.2013.02.003.
    1. Tang XZ, Jo J, Tan AT, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol. 2013;190:3142–3152. doi: 10.4049/jimmunol.1203218.
    1. Kimura K, Kakimi K, Wieland S, et al. Interleukin-18 inhibits hepatitis b virus replication in the livers of transgenic mice. J Virol. 2002;76:10702–10707. doi: 10.1128/JVI.76.21.10702-10707.2002.
    1. Jo J, Tan AT, Ussher JE, et al. Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver. PLoS Pathog. 2014;10:e1004210. doi: 10.1371/journal.ppat.1004210.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren